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ABSTRACT 
 Obesity is characterized by decreased production of the anti-inflammatory hormone, 
adiponectin, increased secretion of pro-inflammatory cytokines and chemokines, and 
increased risk of colon cancer. Although adiponectin has been negatively associated with 
colorectal cancer development in human population, the role of adiponectin in colon 
tumorigenesis is unknown. The anti-inflammatory dietary polyphenol, resveratrol (RSV), 
increases circulating adiponectin concentrations in vivo, and has been shown to be effective 
in prevention of colorectal cancer and obesity-related morbidities. However, the effect of 
RSV supplementation on obesity-linked colorectal cancer had not been previously reported.  
We first used an adiponectin knockout mouse model to investigate the role of 
adiponectin in obesity-associated colorectal cancer. In this study, we showed that in the 
azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced mouse model of colorectal 
cancer, adiponectin genotype, high fat diet, and gender regulate colon carcinogenesis. 
Specifically, development of early lesions (aberrant crypt and mucin-depleted foci) was 
dependent on adiponectin genotype whereas the development of advanced lesions 
(intramucosal and invasive carcinomas) was dependent on diet and sex of the mice. 
Interestingly, adiponectin wildtype (Wt) mice had a greater number of total lesions than the 
knockout (KO) mice suggesting that under pro-inflammatory conditions, the presence of 
adiponectin promotes colonic tumorigenesis.  
We next investigated the interaction between RSV and adiponectin in early colon 
tumorigenesis under obesigenic conditions. In this study, we showed that low-dose dietary 
RSV (20 mg/kg diet) had a tendency to decrease the number of aberrant crypt foci in Wt but 
not KO mice. Similarly, RSV had a tendency to reduce circulating pro-inflammatory 
 xii 
cytokine and insulin concentrations, prevent adipocyte hypertrophy, and increase lean mass 
in Wt mice only. Taken together, RSV had a tendency to interact with adiponectin to 
attenuate tumorigenesis and the metabolic effects of obesity in vivo. We further investigated 
the interaction between adiponectin and RSV in vitro through the use of adipocytes derived 
from adiponectin KO and Wt mice and a colon cancer cell line. Here we showed that in 
adipocytes but not colon cancer cells, the anti-inflammatory effects of RSV are dependent on 
adiponectin.  
Finally, we compared the effects of Sirtuin 1 (Sirt1) and AMP-activated protein 
kinase (AMPK) inhibitors in the attenuation of LPS-induced inflammation by RSV among 
human adipocyte, monocyte, and colon cancer cell lines. Results obtained from this series of 
cell culture experiments, suggests that RSV acted through different mechanisms to inhibit 
chronic LPS-induced inflammation among cell types. In adipocytes, RSV inhibited LPS-
induced inflammation and lipolysis, and Sirt1 and AMPK inhibitors reversed this, 
respectively. In HT29 colon cancer cells, RSV inhibited ROS and proliferation, and the Sirt1 
inhibitor, but not the AMPK inhibitor reversed this. Conversely, RSV’s inhibition of LPS-
induced inflammation in U937 monocytes was not reversed by Sirt1 or AMPK inhibitors. 
Thus, while Sirt1 appears to be important in the effects of RSV in adipocytes and colon 
cancer cells, we did not identify a role for Sirt1 or AMPK in RSV’s anti-inflammatory action 
in monocytes.  
Collectively, our data suggests that adiponectin, diet, and gender interact in the 
development of obesity-associated colon tumorigenesis under pro-inflammatory conditions. 
Moreover, we showed that RSV has a tendency to interact with adiponectin to attenuate 
tumorigenesis and improve the metabolic and inflammatory profile in obesity. These findings 
 xiii 
support the potential use of RSV as an anti-inflammatory dietary supplement aimed at 
prevention of obesity-associated colon tumorigenesis through anti-inflammatory function in 
adipose and colon tissues. Continued research is warranted to further elucidate the role of 
adiponectin and the cell- and tissue-specific actions of RSV in obesity-associated colon 
cancer. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
Introduction 
The prevalence of obesity in developed countries is approaching epidemic levels with 
over one third of the United States population now classified as obese (1). Obesity poses 
serious health and economic concerns in the treatment of co-morbidities such as colorectal 
cancer (2,3,4). The American Cancer Society estimates 102,900 new cases of colon cancer 
and 51,370 colon cancer related deaths in the year 2010 (5). Of these, overweight and obesity 
account for an estimated 14% of cancer deaths in men and 20% in women (6).  
Obesity-associated co-morbidities are attributed to chronic inflammation 
characteristic of an obese metabolic state. As adipocyte size expands in obesity, increased 
adipocyte necrosis and subsequent inflammation signals the infiltration of macrophages into 
the tissue (7). The adipocytes and immune cells in the dysfunctional adipose tissue together 
produce a host of pro-inflammatory mediators. This obese adipokine profile is characterized 
by increased expression of pro-inflammatory adipokines, interleukin-6 (IL-6), tumor necrosis 
factor α (TNFα), macrophage chemotactic protein 1 (MCP-1), and decreased expression of 
the anti-inflammatory adipokine, adiponectin. Furthermore, saturated fatty acids (SFAs) 
released by hypertrophic adipocytes provide additional inflammatory stimulation through 
interaction with toll like receptor 4 (TLR4) and subsequent nuclear factor-κ B (NF-κB) and 
activator protein 1 (AP-1) activation in multiple cell types (8). Collectively, the adipokine 
profile contributes to obesity-associated tumorigenesis through increased oxidative stress, 
proto-oncogene activation, cell proliferation, and immune cell activation.  
In the colon, TLR4 expression is elevated in obesity and is associated with 
adenocarcinoma and increased risk of disease progression (9,10). Increased TLR4 expression 
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in multiple cell types allows for transcription of pro-survival and pro-inflammatory genes 
such as IL-6 and TNFα that in turn directly propagate tumorigenesis (11,12). It has been 
suggested that the obesity-associated decrease in circulating adiponectin concentration also 
plays a role in colon cancer development. This has recently been supported by 
epidemiological studies reporting a negative correlation between circulating adiponectin 
concentrations and risk of colon cancer (13,14). However, adiponectin knockout mouse 
models have yielded controversial results regarding the role of adiponectin in colon 
tumorigenesis (15,16,17). The discrepancies are likely dependent on the different 
tumorigenesis models, inflammatory stimulus, and dietary conditions. 
Resveratrol (RSV) is a polyphenol found in grapes and red wine that has been shown 
to have a preventative role in metabolic dysregulation associated with obesity as well as 
colon tumorigenesis. These functions of RSV are attributed to activation of AMP-activated 
protein kinase (AMPK) and sirtuin 1 (SIRT1). In mice fed a high calorie obesigenic diet, 
RSV supplementation improved metabolic profile and decreased reactive oxygen species 
(ROS) and inflammation (18). Furthermore, dietary RSV has been shown to increase 
circulating adiponectin concentrations (19). The effects of RSV on colitis and colon 
tumorigenesis have been well identified in rodent models. To this end, RSV has been 
demonstrated to inhibit colon cancer cell proliferation and macrophage infiltration through 
attenuation of iNOS expression and NF-B activity (20,21,22). 
 Taken together, this body of literature suggests that obesity-associated colon cancer is 
initiated in part through the pro-inflammatory adipokine environment that includes decreased 
adiponectin expression. Moreover, literature suggests that RSV is an effective means of 
attenuating both the metabolic dysregulation associated with obesity and the development of 
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colon cancer under normal diet conditions through inhibition of NF-κB activity. However, 
the role of RSV in obesity-associated tumorigenesis has not been reported. Furthermore, the 
mechanism of RSV action in cell types involved in obesity-associated colon carcinogenesis 
has not been fully elucidated. A mechanistic understanding of the interaction between 
adipose dysfunction and colon tumorigenesis and the role of RSV in these tissues is critical 
for the development of therapies targeting obesity-associated colon cancer. 
Objective and Specific Aims 
 Our objective is to understand how adiponectin and RSV and their interaction 
regulate obesity-associated colorectal cancer. Our central hypothesis is that adiponectin 
regulates colon tumorigenesis through inhibition of inflammation in colonic epithelial cells. 
We further hypothesize that dietary RSV attenuates colon tumorigenesis in part through 
increased adiponectin concentrations and subsequent disruption of NF-κB and AP-1 
transcription factor activity (Figure 1). The rationale for our work is that an understanding 
of the mechanisms by which RSV regulates obesity-associated colon tumorigenesis will 
promote the development of future therapies targeting pathways involved in RSV signaling. 
Our specific aims are to i) identify the role of adiponectin in obesity-associated colon 
tumorigenesis, ii) determine the importance of adiponectin in attenuation of obesity-
associated colon tumorigenesis by RSV, and iii) elucidate mechanisms by which RSV acts to 
reduce inflammation in cell types involved in obesity-associated colon cancer. 
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Figure 1. The proposed roles of RSV and adiponectin in attenuation of colonic 
tumorigenesis.  
 
Adipocyte hypertrophy results in increased production of cytokines and 
chemokines and decreased production of the anti-inflammatory adipokine, 
adiponectin. Concurrently, macrophages are signaled to infiltrate the tissue to clear 
necrotic adipocytes, which release SFAs and ROS in addition to inflammatory 
mediators. The systemic pro-inflammatory environment characteristic of adipose 
dysfunction promotes activation of TLR4 and the transcription factors NF-κB and 
AP-1 in colonic tissue. This in turn drives tumorigenesis through production of 
pro-survival and pro-inflammatory gene products. We hypothesize that RSV 
inhibits this process through action at adipose and colon tissues. In adipose tissue, 
we hypothesize that RSV increases production of adiponectin and decreases pro-
inflammatory gene expression thus attenuating NF-κB and AP-1 activation in the 
colon. Furthermore, we hypothesize that RSV signals directly at the colon to 
inhibit these pathways by Sirt1 and AMPK activation.   
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CHAPTER 2. REVIEW OF LITERATURE 
Obesity and Co-Morbidities: Role of Chronic Inflammation 
Obesity prevalence and implications 
The incidence of obesity continues to affect a growing proportion of the United States 
population. In 2007-2008, the prevalence of adult obesity (BMI  30) in the United States 
was estimated to be 32.2% for men and 35.5% for women (1). Combined with obesity, the 
prevalence of overweight adults (BMI  25) was a staggering 68% for the same time period. 
This high prevalence of overweight and obesity poses serious burdens both on the health and 
economies of developed countries (2). While the populations of developing countries have a 
lower incidence of obesity than those of developed countries, the rate of obesity is also 
climbing in these countries with highest prevalence in women and rural communities (3,4).   
Visceral or central adiposity is highly correlated with metabolic syndrome (5). The 
third Report of the National Cholesterol Education Program Expert Panel defines metabolic 
syndrome as the presence of at least three of the following criteria: waist circumference 
greater than 102 cm in men and 88 cm in women, 150 mg/dL serum triglycerides, high-
density lipoprotein cholesterol less than 40 mg/dL in men and 50 mg/dL in women, blood 
pressure of at least 130/85 mm Hg, or serum glucose of at least 110 mg/dL (6). Using these 
criteria, the Panel estimated the prevalence of metabolic syndrome to be 23.7% with higher 
prevalence reported for higher age groups, women, and ethnicities (6). In addition to 
metabolic syndrome, obesity predisposes individuals to a host of chronic diseases including 
diabetes mellitus, heart disease, respiratory disease, kidney disease, osteoarthritis, and cancer 
(7). Alternatively, benign obesity occurs in a small subset of the population whom, although 
obese, remains metabolically healthy (8). 
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Obesity-associated chronic inflammation and co-morbidities 
Obesity is often characterized by low-grade, chronic inflammation. While acute 
inflammation is a critical step in a host’s immune response to pathogen and injury, chronic 
inflammation is compromising to overall health by several mechanisms. The main outcomes 
of an inflammatory response are increased membrane permeability, infiltration of immune 
cells into tissue, proliferation, and angiogenesis. These functions are accomplished by 
inflammatory mediators that can have deleterious effects when chronically elevated in the 
circulation and tissues. Inflammatory mediators include cytokines, chemokines, adhesion 
molecules, growth factors, angiogenic factors, and reactive oxygen species (ROS) that 
collectively act to promote development of obesity-related co-morbidities.  
Adipose expansion and inflammation 
 Adipose tissue is composed of an integrated network of adipocytes, endothelial cells, 
immune cells, and connective tissue that functions as a dynamic endocrine organ. The cell 
types that make up adipose tissue secrete a myriad of hormones, cytokines, and chemokines 
collectively referred to as adipokines (9,10). The secretion of adipokines is a highly regulated 
process that in a normal state has a net anti-inflammatory effect. However, disruption of the 
normal milieu in obesity results in a shift to a pro-inflammatory adipokine profile. Nearly all 
co-morbidities of obesity can be attributed, at least in part, to chronic inflammation (11,12). 
In obesity, inflammation is initiated by adipocyte expansion and increased cell 
turnover (13,14). Adipocyte turnover, or remodeling, requires recruitment of macrophages to 
aide in necrosis through formation of crown-like structures around the necrotic adipocyte 
(15). Cytokines and chemokines secreted by the activated macrophages along with nucleic 
acids released from necrotic adipocytes stimulate local inflammation in surrounding adipose 
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tissue (16). Adipose inflammation is mediated by pro-inflammatory adipokines, which play 
an integral role in further monocyte and macrophage recruitment (17).  
Saturated free fatty acids and inflammation 
An increase in circulating concentrations of free fatty acids (FFAs) is also observed in 
obesity. The cause of this phenomenon is two-fold: 1) down-regulation of FFA clearance 
from blood and 2) increased FFA release from adipocyte turnover. Saturated fatty acids 
(SFAs) have been causally linked to stimulation of inflammation in adipocytes and 
macrophages. Daniel Hwang’s group was one of the first to demonstrate an inflammatory 
response to SFA in RAW 264.7 macrophages (18). In this study, the SFA lauric acid, 
induced inducible nitric oxide synthase (iNOS) and cylooxygenase 2 (COX2) expression in 
macrophages through activation of toll like receptor 4 (TLR4) and nuclear factor κ B (NF-
B). In adipocytes, SFAs cause an inflammatory response through TLR4 and TLR2 that 
results in activator protein 1 (AP-1), c-Jun N-terminal kinase (JNK), and NF-κB activation 
(19,20,21). Moreover, inhibition of TLR-mediated signaling blunts basal and palmitate-
stimulated pro-inflammatory cytokine secretion and NF-B activation in vitro (22) and 
partially protects against obesity-induced inflammation in vivo (23,24).  
Increased FFA release from adipocytes also results in ectopic lipid deposition in non-
adipocytes referred to as lipotoxicity. Lipotoxicity describes the cytotoxic accumulation of 
lipid in liver, pancreas  cells, skeletal muscle, and cardiomyocytes (25). The cytotoxic lipid 
and ceramide accumulation causes apoptosis of non-adipocytes, thereby contributing to 
insulin resistance and metabolic syndrome (26,27).  
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Role of Adipokines in Obesity-Associated Inflammation 
Pro-inflammatory cytokines  
Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF) are cytokines secreted 
from adipose tissue that act both locally on adipose tissue and systemically on multiple cell 
types to mediate an inflammatory immune response (28,29). Adipose production of IL-6 and 
TNF is elevated in obesity (28,30,31), and decreases with weight loss (32,33). Elevated 
cytokine concentrations contribute to the pathogenesis of many obesity-associated diseases 
including insulin resistance, cardiovascular disease, hepatic inflammation, and many cancers 
(34).  
IL-6. The transcription of IL-6 can be activated by multiple transcription factors 
involved in adipose inflammation including NF-B, AP-1, and CCAAT/Enhancer binding 
protein beta (C/EBP-) (35). Adipose tissue is a major source of IL-6, contributing up to one 
third of circulating IL-6 in healthy adults (29). IL-6 binds its receptor, IL-6R or soluble IL-
6R, in multiple cell types and complexes with gp130 to activate a downstream signaling 
cascade beginning with janus kinase (Jak1) binding and subsequent activation of signal 
transducer and activator of transcription (STAT3) (36). IL-6 is key activator of liver acute 
phase protein synthesis and contributes to angiogenesis and endothelial dysfunction through 
increased vascular endothelial growth factor (VEGF) and plasminogen activator inhibitor 1 
(PAI-1) expression, respectively (37,38,39).  
The importance of IL-6 has been demonstrated in studies investigating the common 
IL-6 -174G>C polymorphism in the promoter region of the human IL-6 gene. The IL-6 
genotype significantly affects circulating IL-6 concentrations and risk of developing insulin 
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resistance and other obesity-associated metabolic complications (40,41). The role of IL-6 has 
been further defined through the use of transgenic animal models. Over-expression of IL-6 in 
muscle of mice led to hyperinsulinemia and impaired glucose uptake despite a reduction in 
adipocyte size and body weight (42). These mice also had increased F4/80 macrophage 
infiltration into the liver. The reduction in adipocyte size and weight is due to increased 
energy expenditure, the opposite of which is also evident in IL-6 deficient mice. IL-6 
deficient mice develop obesity and leptin resistance that are reversed with IL-6 injections 
(43).  
TNF.  In obese individuals compared to lean, adipose production of TNF increases 
2.5 fold (44). Like IL-6, TNF is regulated by NF-B activation, and acts in both an 
autocrine and paracrine manner. TNF signals through two transmembrane receptors, TNFα 
Receptor 1 (TNFR1) and 2 (TNFR2) to activate NF-B, JNK, and mitogen activated protein 
kinases (MAPK) such as extracellular signal-regulated protein kinase (ERK1/2) and p38 as 
reviewed by Cawthorn and Sethi (45). These signaling cascades result in propagation of 
inflammation, and over time, development of insulin resistance through decreased GLUT4 
expression (46). TNF knockout and TNFR knockout mice have reduced, but not diminished 
adiposity and are partially protected from loss of insulin sensitivity compared to mice with 
functional TNF fed a high fat diet (47). TNFα has also been demonstrated to be responsible 
for the obesity-associated increase in the adhesion molecule, E-selectin (48). 
Chemokines 
Chemokines such are macrophage chemotactic protein 1 (MCP-1, also known as 
CCL2) and macrophage inflammatory protein (MIP1, also known as CCL3) are important 
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mediators of obesity-induced inflammation and co-morbidities. The primary functions of 
chemokines are recruitment of immune cells to sites of inflammation, activation of 
inflammatory immune response, and control of cell migration through tissues. Adipose 
expression of MCP-1 and MIP1 is elevated in obesity but is not consistently reflected in 
serum concentrations of these chemokines due to their local action (49,50). In addition to the 
primary role of chemokines in immune function, chemokines also function in regulation of 
glucose homeostasis in adipose tissue under conditions of obesity.  
Of these chemokines, MCP-1 has been most prominently linked to adipose 
inflammation and adipose-linked co-morbidities of obesity. Over-expression of MCP-1 in 
adipose leads to elevated IL-6 and TNF adipose expression and insulin resistance (51). In 
adipocyte cell culture, MCP-1 causes decreased glucose uptake through down-regulation of 
GLUT4 (52). Chronic MCP-1 infusion in mice resulted in development of insulin resistance, 
macrophage infiltration in adipose tissue, and hepatic steatosis (53). Similarly, over-
expression of MCP-1 in adipose tissue of mice using the adipocyte promoter (aP2) resulted in 
macrophage accumulation in adipose tissue, insulin resistance, and increased circulating pro-
inflammatory cytokine and FFA concentrations (51). Conversely, obese mice lacking MCP-1 
receptor (CCR2) have reduced macrophage infiltration into adipose tissue, decreased hepatic 
steatosis, and improved insulin sensitivity (54). 
Adiponectin 
Adiponectin (also known as Acrp30 and AdipoQ) is an anti-inflammatory and 
insulin-sensitizing hormone produced primarily by adipocytes. The 30 kDa protein circulates 
in three forms with distinct biological activity and functions: trimer, hexamer, and high 
molecular weight (HMW). Agonists of the adiponectin promoter, peroxisome proliferator-
 13 
activated receptor γ (PPAR) have been shown to increase adiponectin expression (55) and 
up-regulate the enzyme responsible for adiponectin multimerization, disulfide-bond A 
oxidoreductase-like protein (DsbA-L), and other endoplasmic reticulum proteins involved in 
adiponectin processing and stabilization (56). A feed-forward mechanism has also been 
demonstrated between adiponectin and PPARγ (57). Adiponectin concentrations decrease as 
adipose tissue expands in obesity. This is accomplished by down-regulation of DsbA-L and 
PPARγ (58).  
Adiponectin signals through two 7-transmembrane receptors, adiponectin receptor 1 
(AdipoR1) and 2 (AdipoR2) expressed differentially on multiple cell types (59). Several 
binding proteins have recently been implicated in adiponectin signaling including adaptor 
protein containing PH domain, PTB domain and leucine zipper motif 1 (APPL1), 
endoplasmic reticulum protein 46 (ERp46), receptor for activated protein kinase C1 
(RACK1) and protein kinase CK2β (60). Downstream signaling pathways from AdipoR1 and 
AdipoR2 have not been fully elucidated. However, targeted disruption of AdipoR1 and 
AdipoR2 revealed preferential downstream activation of AMPK and PPAR, respectively 
(61). Additionally, both receptors regulate ERK 1/2, p38, JNK, and STAT3 signaling 
pathways (62,63). The involvement of these signaling pathways in obesity and its co-
morbidities makes adiponectin a promising therapeutic target.  
In a long term mouse obesity study, Bullen et al. reported decreased adiponectin and 
increased adiponectin receptors after prolonged high fat diet feeding in mice (64). The 
elevated inflammation that often accompanies obesity is likely due in part to decreased 
adiponectin production. In adipocytes, adiponectin inhibits lipopolysaccaride (LPS)-induced 
NF-B activation and IL-6 and MCP-1 production (57,65). Adiponectin has been shown to 
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inhibit pro-inflammatory macrophage signaling and promotes activation of M2 macrophages 
to aid in resolution of a pro-inflammatory response, in part through AMPK and PPAR 
signaling (66,67). Obesity-induced decrease in circulating adiponectin concentrations 
(especially HMW) may also promote insulin resistance. Adiponectin participates in 
regulation of glucose uptake by increasing APPL1 and Rab5 binding to AdipoRs, resulting in 
GLUT4 translocation (68,69). Insulin sensitizing effects of adiponectin are mediated by 
AMPK and PPARα activation via AdipoR1 and AdipoR2, respectively (70).   
Pathogenesis and Mechanisms of Obesity-Associated Colon Cancer 
Obesity and colon cancer risk 
The National Program of Cancer Registries reported more than 800,000 cases of 
colon cancer in the United States from the years 1999 to 2004 (71). This report also revealed 
a greater gender disparity (males > females) in people older than 65 yr and a greater race 
disparity (blacks > other races) in people under the age of 65. In the year 2010 alone, the 
American Cancer Society estimated 102,900 new cases of colon cancer and 51,370 colon 
cancer related deaths (72). Obesity is associated both with elevated risk of colorectal cancer 
(73,74) and with colon cancer reoccurrence and mortality (75). Of total cancer deaths in the 
United States, overweight and obesity account for an estimated 14% of cancer deaths in men 
and 20% in women (76).  
Molecular and pathological progression of obesity-linked colon cancer 
The multi-hit model is widely used to describe the process of spontaneous colon 
carcinogenesis. The premise of this model is that of accumulated damage. Multiple “hits” or 
genetic mutations are required to evade clearance by the immune system and allow 
promotion and progression of a tumor cell. The majority of colon cancer is initiated by a 
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somatic or germ-line mutation in the Wnt pathway adenomatous polyposis coli (APC) gene 
or in mismatch repair genes, MLH and MSH (77). Somatic mutations can result as a 
consequence of inflammation-linked oxidative DNA damage. If not detected, these initial 
molecular “hits” progress to hyperplasia and formation of small lesions such as aberrant 
crypt foci (ACF) that are frequently accompanied by depletion of mucin-secreting goblet 
cells.  
The progression from ACF to adenoma is often caused by mutation in a proto-
oncogene such as K-ras, resulting in proliferation of the tumor cells. Up-regulation of proto-
oncogenes and angiogenic factors is stimulated by growth factors and pro-inflammatory 
cytokines common to the obese serum profile. Inflammation in obesity-induced colonic 
epithelium may also be derived from increased intestinal endotoxin transport and interaction 
of saturated FFAs with TLRs (78). Adenomas are highly associated with elevated 
cyclooxygenase 2 (COX-2) due to increased prostaglandin signaling and are characterized by 
dysplasia and often display a vascularized stalk-like structure. The transition from an 
adenoma to a malignant phenotype or carcinoma is often accompanied by additional 
mutations in the tumor suppressor genes p53 and TGF- Receptor. The metastatic potential 
of carcinomas often results in invasion of the submucosa layer and entry into the circulation. 
Colon cancer cells primarily metastasize to the liver via the portal system connecting the 
intestinal tract and liver. In addition to APC, K-ras, and p53 mutations commonly observed 
in human colorectal cancer, alterations in DNA methylation and chromatin regulation have 
recently been identified as a common event in human colon cancer (79). 
Evidence now suggests that location of the tumor within the colon may present with 
different characteristics. Development of tumors in the right vs. left side of the colon is 
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influenced by age, gender, and environmental factors (80,81). Along these lines, histological 
features and tumor subtype are influenced by colon location (proximal vs. distal and right vs. 
left) (82). MiRNA profile has also been shown to vary between proximal, distal, and rectal 
colonic tumors (83). Thus, it is becoming increasingly important to evaluate specific tumor 
subtypes and locations separately when assessing colon carcinogenesis. 
Research animal colon cancer models 
Chemical induction of animal carcinogenesis is aimed to imitate spontaneous gene 
carcinogenesis pathway in humans. The most effective chemical carcinogenesis strategies 
involve both initiation and promotion. In a rodent model of colon cancer, the most chemical 
common initiator is azoxymethane (AOM), a stable metabolite of dimethylhydrazine. AOM 
is a precursor to methylazoxymethanol, a metabolite that initiates PI3K/Akt pathways 
(84,85). Like spontaneous colon carcinogenesis in humans, AOM-induced carcinogenesis 
causes β-catenin accumulation in the nucleus mutation of K-ras. However, AOM-induced 
carcinogenesis typically does not cause p53 or APC mutations as are often observed in 
human cancer (86,87). Irritants such as dextran sodium sulfate (DSS) are often combined 
with AOM to promote carcinogenesis through inflammation and oxidative stress (88). The 
choice of rodent strain is important as strains respond differentially to AOM/DSS treatment 
with Balb/c and C57BL/6 mice developing great number of carcinomas than C3H/HeN and 
DBA/2N strains (89). 
Mechanisms of obesity-linked colorectal carcinogenesis 
Obesity contributes to colorectal tumorigenesis through dysregulation of adipokine, 
cytokine, chemokine, ROS, FFA, and insulin production as summarized in Figure 2.  
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Adipokines and colon cancer 
The adipokines, adiponectin and leptin, are linked to obesity-associated colon cancer 
risk. Several human studies have reported an association between decreased serum 
adiponectin concentrations and increased risk and severity of colorectal cancers (90,91,92). 
Furthermore, differential AdipoR1 and AdipoR2 expression has been detected in human 
tumors of the colon compared to normal colon tissue suggesting a possible role for 
adiponectin signaling in colon tumorigenesis (93,94,95). However, there also exist reports of 
no association between circulating adiponectin and colon cancer, illustrating the multi-
factorial nature of metabolic syndrome and tumor development (96).  
Adiponectin knockout mouse models have produced equally inconsistent results. The 
first in vivo mouse model of adiponectin deficiency and colitis was reported in 2006 by 
Nishihara, et al. (97). In this study, authors reported a protective effect of adiponectin against 
colitis after administration of 0.5% DSS for 15 days. The study was complicated by the use 
of non-littermate knockout and wild-type mice and the high basal circulating concentration of 
Figure 2. Progression of obesity-
associated colon tumorigenesis. The 
hypertrophy of adipose tissue in obesity 
results in dysregulation of adipokine 
secretion and subsequent transition to a 
pro-inflammatory milieu characterized by 
increased production of cytokines, 
chemokines, ROS, and FFAs. This 
environment promotes colon distress and 
tumorigenesis, further contributing to 
chronic inflammation and propagation of 
tissue dysfunction. 
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TNFα in these mice. The following year, Fayad et al. reported that adiponectin deficient mice 
were protected from DSS-induced colitis compared to wild-type littermates (98). The authors 
proposed that adiponectin was inhibiting the activity of epidermal growth factor and heparin 
binding epidermal growth factor through direct binding, thereby inhibiting their protective 
activity in DSS-induced colitis. The first study using AOM-induced tumorigenesis and high 
saturated fat diet-induced obesity in an adiponectin deficient mouse model was reported in 
2008 by Fujisawa et al. (99). In contrast to results reported in the DSS-model, adiponectin 
was protective against obesity associated colon cancer development in the AOM model. This 
is somewhat surprising considering the pro-inflammatory potential of fatty acids. The 
investigation of the role of adiponectin in colon carcinogenesis has been complicated by the 
varied effects of carcinogenic agents, diet, and model. Further research is warranted to 
identify the specific effects of experimental factors and their interaction with adiponectin. 
Mechanistically, adiponectin is a logical molecular target for obesity-linked colon 
cancer prevention due to its role in AMPK and PPAR activation and inhibition of NF-κB 
(100,101,102,103). In support of this, two groups have recently demonstrated that 
adiponectin exerts an AMPK-dependent anti-proliferative effect on human colon cancer cells 
(102,104). Moreover, PPARγ, the transcription factor responsible for induction of 
adiponectin transcript, is considered anti-neoplastic in colon cancer (100). Microarray 
analysis of multiple cancer cell lines treated with full length adiponectin revealed a broad 
mechanism of action with most differentially expressed genes falling within inflammation, 
stress response, and proliferation regulation (105). Interestingly, it was recently shown that 
the effect of adiponectin on cancer cell cancer proliferation is glucose-dependent whereby 
adiponectin supports DLD-1 colon cancer cell survival in low glucose but inhibits 
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proliferation under high glucose conditions (106). In contrast to this, pro-inflammatory 
effects of adiponectin in monocytic cell and colon cancer cells have been reported in vitro 
(107,108). Taken together, adiponectin is an attractive target for obesity-associated colon 
cancer, but further research is needed to completely identify the potential actions of 
adiponectin.  
Leptin has been implicated in colon cancer cell proliferation and invasiveness through 
activation of key pathways including phosphoinositide 3-kinase (PI3K), Src, Wnt, NF-κB, 
and insulin-like growth factor (IGF) pathways (109,110,111). Interestingly, colon cancer 
cells treated with conditioned media from leptin-deficient ob/ob or Wt adipocytes showed 
that leptin mediates the proliferative effect of adipocytes (112,113). Conversely, Ealey et al. 
reported that that leptin does not play a role in early lesion formation using ob/ob and db/db 
mice (114).  
Rather than consider adiponectin and leptin separately as risk factors, the 
leptin:adiponectin ratio has recently emerged as a positive risk factor for colon cancer (115). 
In breast cancer cell lines, an interaction was observed between leptin and adiponectin 
whereby adiponectin treatment caused a decrease in leptin and leptin receptor expression and 
leptin treatment decreases AdipoR1 expression (116). Moreover, when adiponectin and leptin 
are administered to breast cancer cells concurrently, the anti-proliferative effects of 
adiponectin and pro-proliferative effects of leptin are negated. Further interactions have been 
reported between leptin and adiponectin whereby adiponectin rescued the cancer-promoting 
effects of leptin on p53, Bcl2, and NF-κB in prostate, hepatic, and colon cancer cells 
(117,118,119).  
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Inflammation and colon cancer 
Inflammation controls a fine balance between tumor suppression and promotion. An 
acute inflammatory response can promote immune recognition and clearance of tumor cells 
whereas chronic inflammation contributes to genomic instability, angiogenesis, and 
proliferation of tumor cells. A strong causative association between inflammation and colon 
cancer has been established in inflammatory diseases such as Crohn’s disease and colitis 
(120,121). This is demonstrated by data showing NSAIDs (non-steroidal anti-inflammatory 
drugs) such as aspirin effectively prevent colorectal adenoma development (122,123).  
Expression of the pro-inflammatory cytokines IL-6 and TNF is up-regulated in 
adipose tissue in obesity. In addition to autocrine and paracrine effects on adipose tissue, 
adipose-derived IL-6 and TNF can signal in an endocrine manner to activate NF-B in 
tumor cells. In turn, the tumor cells increase production of cytokines, chemokines, and COX2 
leading to a feed-forward propagation of tumor cell proliferation and growth (124,125). This 
association was demonstrated in obese subjects who underwent diet-induced weight loss 
(126). Weight loss of on average 10% of initial body weight resulted in decreased colonic 
expression of MCP-1, TNFα, and IL-1β, a 42% reduction in macrophage number, and 
downregulation of STAT3 and NF-κB pathways. IL-6 itself drives colon cell proliferation 
(127) and contributes to damage of colonic tissue through increased expression of MMP, 
ICAM, and VCAM and increased immune cell infiltration (35). The importance of TNFα in 
colon cancer has been demonstrated through targeted disruption of TNFα signaling. Anti-
TNFα antibody blocked NF-κB activation in epithelial cells (128). In line with this, mice 
lacking TNF Receptor p55 were protected from AOM/DSS-induced immune cell infiltration, 
mucosal damage, and tumorigenesis compared to wild-type mice (129).  
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The effects of pro-inflammatory cytokines on tumorigenesis are mediated in part 
through TLR4 and NF-κB activation. In obesity, TLR4 expression is up-regulated by 
increased circulating and colonic endotoxin as well as adipose- and diet-derived SFAs 
(78,130). TLR4 expression is associated with adenocarcinoma and increased risk of disease 
progression (131,132). In support of this, mice transgenic for constitutive activation of TLR4 
were more susceptible to AOM/DSS-induced carcinogenesis (132). Moreover, amelioration 
of TLR4 signaling in DSS models of colitis reduced disease severity, decreased MAPK p38, 
c-Jun, IL-6, and TNFα mucosal expression, and inhibited macrophage and dendritic cell 
infiltration (133,134). However, TLR4 blockage also inhibited repair of DSS-induced 
mucosal tissue damage (134), illustrating the importance of inflammation-mediated tissue 
repair to colonic integrity. The duel roles of TLR4 are explained by transcription of growth 
factors, cytokines, and chemokines by NF-κB that both promote tumorigenesis and tissue 
repair.  
Oxidative stress and colon cancer 
Up-regulation of ROS production occurs upon activation of NF-κB in colonic 
epithelium, immune cells, and adipose tissue in obesity (135,136,137). When produced in 
large quantities, ROS overwhelm the oxidant:anti-oxidant balance, resulting in oxidative 
damage to DNA (138). The persistence of ROS-induced DNA damage leads to genomic 
instability and ultimately formation of a cancer cell (139). This is supported by multiple 
human studies showing a strong association between oxidative stress and colon cancer 
(140,141,142). ROS also activates molecular pathways that play a role in carcinogenesis such 
as the MAPKs, p38 and JNK (143), and cytokine production by NF-κB (144).  
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Insulin dysregulation and colon cancer 
High insulin and glucose are associated with increased risk for colorectal adenomas 
(145,146). Moreover, diabetes is an independent risk factor for several cancers types, 
including colon, with risk increasing across BMI categories (146,147,148). These 
associations support the hypothesis that obesity-induced hyperinsulinemia and increased 
active IGF-1 promote colon cancer (149). Hyperinsulinemia promotes colon cancer cell 
proliferation through activation of the mammalian target of rapamycin (mTOR)/c-Myc 
pathway and nuclear accumulation of β-catenin (150). Chronic injections of insulin increased 
ACF multiplicity and tumors in rats after AOM injections (151,152). Blockage of 
downstream insulin signaling through insulin receptor substrate 1 (IRS-1) inhibition results 
in attenuation of colon cancer cell proliferation (153). Moreover, mice with muscle-specific 
insulin receptor knockout develop fewer AOM-induced ACF than mice with functional 
insulin receptor (154). 
IGF-1 Receptor (IGF-1R) is over-expressed in human adenocarcinoma (155), and 
expression of IGF-1R is positively associated with severity and metastasis of colorectal 
cancer (156). IGF-1 mediates proliferation and apoptosis signals for many cell types, and as 
such has been highly implicated in promotion of tumorigenesis (157). The RNAi knockdown 
of IGF-1R in vitro causes chemosensitization and reduced proliferation of human colon 
cancer cells (158). Liver-specific IGF-1 deficient mice have reduced circulating IGF-1 
concentrations and show attenuation of AOM-induced colorectal proliferation and 
tumorigenesis (159). Furthermore, growth of human colorectal tumors injected 
intrahepatically (a common metastasis site) in mice was inhibited by IGF-1R antibody (160). 
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The link between insulin dysregulation and colon cancer is further demonstrated by 
diabetes drugs that have been shown to attenuate colon tumorigenesis. Pioglitazone, a PPAR 
agonist, reduces ACF multiplicity in humans (161). Moreover, Metformin reduces ACF 
development in AOM mouse model through AMP-activated protein kinase (AMPK)-
dependent decrease of IGF-1 (162,163). In a retrospective cohort analysis of human diabetic 
subjects on various diabetes treatments, those patients receiving insulin therapy had an 
elevated risk of colorectal cancer whereas those patients taking Metformin had the lowest 
risk of colorectal cancer (164).  
Dietary fat and colon cancer  
There is a paucity of human data relating dietary fat and colon cancer risk, and the 
currently published data is inconsistent. Older epidemiological studies report a positive 
association between dietary fat and colon cancer (165,166,167,168,169). Conversely, more 
recent prospective and retrospective human studies have reported little or no association 
between saturated fat and colon cancer (170,171,172,173). There is yet another set of 
literature that argues general caloric intake rather than saturated fat contributes to colon 
cancer risk (165,174,175). Interestingly, dietary fat restriction increased incidence of CRC 
reoccurrence in patients over a 4 year period (176). These controversial results are the 
consequence of varied statistical methods for inclusion of genetic mutations, food 
composition, degree of cancer severity, and collection of subject diet information.  
In contrast to human data, a causal association between dietary fat type or amount and 
development of colon cancer has been reported in several rodent carcinogenesis models. One 
of the first reports of the role of fat quantity and type in colon carcinogenesis was performed 
by Reddy et al. in 1976 (177). In this study, diets of 20% corn oil or 20% lard increased 
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dimethylhydrazine-induced colon tumor incidence compared to 5% fat diets, but there were 
no differences observed between fat type and incidence. In a follow-up study, Reddy et al. 
demonstrated that type of fat could modify colon cancer development where replacement of 
75% of a 23.5% corn oil diet with fish oil resulted in a significant reduction in development 
of AOM-induced tumors (178). Rao and colleagues further investigated the effects of high 
saturated fat, high omega-3 fat, or low fat corn oil diets in an AOM rat model (179). In this 
study, rats fed the high saturated fat diet developed greater colon tumor multiplicity, 
decreased colonic apoptosis, and higher COX-2 activity than other diets. A similar role for 
high saturated fat has been reported in benzo(a)pyrene and tribromomethane models of 
carcinogenesis and hepatic metastasis (180,181,182). Together, these results suggest that 
both amount and type of fat are important in regulation of colon tumorigenesis. 
Recently, a more mechanistic relationship has been built between dietary fat and 
colon cancer. Endo et al. showed that a high fat but not low fat diet promoted ACF formation 
and colon cancer cell proliferation through the JNK pathway in an AOM mouse model (183). 
In support of this, circulating triacylglycerols are positively associated with colonic oxidative 
stress and lesion formation (184). The pro-inflammatory effects of saturated fats on adipose 
tissue discussed above provide support for the data that suggests saturated fats potentiate 
colon carcinogenesis. It is possible that saturated fat elicits a toll like receptor-mediated 
immune response in the colon as in adipose tissue. It is also plausible that saturated fat-
induced adipokines act on the colon to propagate inflammation and carcinogenesis. In 
addition to induction of inflammation, a potential mechanism by which high fat diets 
promote colon carcinogenesis is through increased bile acid synthesis and bile acid-induced 
DNA oxidative damage. Bile acids have been shown to be carcinogenic (185) and to be 
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increased under high fat diet conditions (186,187). However, animal studies aimed at this 
mechanism have not yet been reported. Further investigation is warranted in this field to 
identify the effects of dietary fat and obesity on cancer risk.  
Resveratrol Functional Properties and Bioavailability 
Functional properties 
Resveratrol (trans-3,5,4’ trihydroxystilbene, RSV) is a polyphenol found in grapes 
and red wine among other plant products. RSV is synthesized in plant species in response to 
stress by the enzyme RSV synthase (trihydroxystilbene synthase) (188). The polyphenolic 
and lipophilic structure of RSV account for its antioxidant properties as well as its uptake by 
tissues. RSV primarily exists in foods as its glucoside, trans-piceid (189). However, RSV 
aglycone is the form most widely studied, commercially available, and most commonly used 
in supplements.  
Absorption, metabolism, and bioavailability 
The bioavailability of RSV was investigated by Walle, et al. through the tracking of 
25 mg 
14
C-RSV administered orally to six human subjects (190). Walle, et al. reported high 
absorption (70%) with 2 M peak plasma metabolite and RSV concentrations occurring at 1 
hr. A second peak of 1.3 M occurred at 6 hr. after intake. Unfortunately, amounts of 
unchanged 
14
C-RSV were not well detected (<5 ng/ml) in the serum. The primary metabolite 
of RSV detected in the serum was the sulfate-conjugate (although the glucuronide form was 
also detected). The fate of this metabolite is currently unknown regarding tissue uptake and 
metabolism. RSV is ultimately eliminated in the urine (191) and is not reportedly toxic (192). 
A similar study was performed following 
14
C-RSV after oral administration in Balb/c mice 
(193). In consensus with the human study, whole blood circulation concentrations were 1.5 
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M. However, the use of mice allowed researchers to evaluate tissue concentrations of RSV 
revealing high accumulation in the liver and kidney (25 M and 50 M, respectively). Taken 
together, these studies provide extremely valuable information regarding the metabolic 
processing of RSV and indicate that RSV may indeed be a realistic therapeutic tool. 
There are several factors that may affect circulating RSV detection. In light of a 
recent report showing RSV conjugates are detected better in whole blood than serum (194), 
RSV may circulate at higher concentrations than previous studies have reported. 
Additionally, the cis isomer of resveratrol is rarely measured specifically, but exists in the 
circulation. However, the biological activity of cis-RSV is largely unknown due to the lack of 
commercial availability. Recent evidence suggests that RSV bioavailability may also be 
affected by circadian rhythm and that highest bioavailability occurs in the morning (195).  
RSV absorption and metabolism has also been investigated in vitro through the use of 
the Caco-2 intestinal cell culture model (196,197). RSV aglycone is better absorbed than the 
glucoside trans-piceid due to its lipophilic properties allowing for passive diffusion of RSV 
while trans-piceid is transported by SGLT-1 (197). It has been well established that both 
RSV and piceid are metabolized upon uptake into the enterocyte. Piceid may be hydrolyzed 
to release RSV by the enzymes -glucosidase in the cytosol or the membrane-bound lactase 
phlorizin hydrolase (198,199). RSV is primarily modified by sulfonation and 
glucuronidation. As demonstrated in Caco-2 cells, these modifications may render RSV less 
bioactive once absorbed (196). In addition to RSV metabolites, RSV is also found circulating 
bound to serum albumin or hemoglobin, resulting in a longer half-life (200). 
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Resveratrol and Obesity 
The promising anti-obesity effects of RSV were introduced in 2006 when Sinclair and 
colleagues showed RSV supplementation (0.04%) increased survivability in high calorie-fed 
mice (201). This effect was accompanied by increased insulin sensitivity, decreased hepatic 
lipid accumulation, increased mitochondrial function, and improved overall metabolic 
profile. In response to this study, a number of molecular targets have been identified linking 
RSV with anti-obesity effects.  
Primary molecular targets 
SIRT1. It is well established that RSV is a SIRT1 activator. SIRT1 is an NAD
+
-
dependent deacetylase of histones, transcription factors, and other non-histone proteins 
located in the nucleus of several cell types including white adipose, skeletal muscle, and liver 
(202). Borra, et al. proposed that RSV directly binds SIRT1 thereby inducing a 
conformational change that enables interaction between SIRT1 and its substrate group (203). 
SIRT1 activates a wide range of genes including PPAR, PPARγ CoActivator 1α (PGC-1α), 
and FoxO1. These pathways are critically involved in adipocyte differentiation, metabolism, 
and regulation of ROS (204). In general, the effects of resveratrol are not negated when 
SIRT1 is knocked out, but rather diminished suggesting an additional route of action of 
resveratrol (205).  
AMPK. In addition to SIRT1, AMPK has recently been recognized as a primary 
target of RSV. The mechanism by which RSV activates AMPK is currently unknown. It has 
been proposed that AMPK activation is linked to SIRT1 activation (206). This is supported 
by evidence that SIRT1 regulates LKB1, the upstream AMPK activating kinase (207). 
However, acute RSV-induced LKB1 activation of AMPK has been demonstrated 
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independent of SIRT1 (208). Moreover, it is now recognized that PGC-1α activation requires 
both SIRT1 deacetylation and AMPK phosphorylation (209). The individual effects of 
AMPK activation are on fatty acid oxidation through phosphorylation of acetyl CoA 
carboxylase (ACC) and stimulation of glucose transport (210,211).  
Anti-obesity physiological effects 
Adipokines and inflammation 
The anti-inflammatory properties of RSV are mediated in part through adipokine 
regulation. Numerous studies have reported increased adiponectin production in response to 
RSV treatment both in vitro (212,213,214) and in vivo (215). In an intervention study of 
participants with elevated serum CRP, subjects given a supplement containing RSV among 
other antioxidants had a 7% increase adiponectin concentrations and a decrease in the overall 
inflammation (216). Until recently, the mechanism by which RSV increased adiponectin 
concentrations was unknown because expression and stability of the adiponectin transcription 
factor, PPARγ, is reportedly down-regulated by RSV in adipocytes (217,218). Recently, 
Wang, et al. reported one potential mechanism of adiponectin regulation by RSV in which 
RSV activates DsbA-L, the enzyme responsible for multimerization of adiponectin to form 
its HMW structure (214). They further described the activation of DsbA-L as Sirt1-
independent, and AMPK- and Foxo1-dependent pathway both in vivo and in vitro.  
Decreased pro-inflammatory cytokine production in adipocytes and macrophages is 
another mechanism whereby RSV ameliorates obesity-associated inflammation. In 3T3-L1 
adipocytes, RSV suppressed macrophage conditioned media-induced IL-6 and TNF 
secretion through NF-κB p65 inhibition (213). RSV also suppressed MCP-1, COX2, IL-6, 
and IL-1β expression in TNFα-stimulated adipocytes through NF-κB inhibition (219,220). 
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Using human macrophages and adipocytes, McIntosh’s group recently demonstrated a role 
for MAPKs (JNK and p38) and AP-1 in addition to NF-κB in the anti-inflammatory effects 
of a grape powder extract containing RSV (221). A similar study was conducted using 
human monocytes wherein RSV inhibited LPS- and TNFα-induced MAPK, NF-κB, and AP-
1 pathways in monocytes and lymphatic cells (222). The inhibition of pro-inflammatory 
cytokine and chemokine secretion by RSV in adipose tissue and adipocytes has been shown 
to be SIRT1-dependent (205,223).   
RSV has also been shown to alleviate inflammation-induced oxidative stress. In 
TNFα-treated adipocytes, RSV decreased ROS production and increased glutathione 
peroxidase, superoxide dismutase, and glutathione S-transferase activity (224). Moreover, 
RSV functions to prevent hepatic steatosis (201,225) and improve endothelial function (226) 
through attenuation of ROS production. 
Energy balance and metabolism 
RSV has been demonstrated to improve the obese metabolic profile through 
increasing fatty acid oxidation, glucose uptake, and insulin sensitivity. Growth of both pre-
adipocytes (205) and mature adipocytes (217) was down-regulated by RSV through 
increased mitochondrial activity and decreased expression of genes involved in adipogenesis 
and fatty acid synthesis. Similarly, obese Zucker diabetic rats treated with long-term daily 
RSV supplementation (10mg/kg body weight) had increased liver AMPK phosphorylation 
(Thr172) and ACC phosphorylation, resulting in increased β-oxidation (215). RSV improved 
insulin-stimulated glucose uptake in C2C12 myotubes (210) and adipocytes (205,213) 
through inhibition of IRS-1 serine phosphorylation and increase in tyrosine phosphorylation. 
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Importantly, RSV has also been shown to activate hepatic PGC-1α thereby allowing for 
greater thermogenic potential (201,227). 
Resveratrol and Colon Cancer 
RSV is a promising chemotherapeutic agent due to its ability to attenuate initiation 
and progression of carcinogen-induced colon cancer (228,229,230,231). The molecular 
targets of RSV, SIRT1 and AMPK, function to attenuate colon carcinogenesis by 
mechanisms similar to its anti-obesity effects: inflammation, oxidative stress, and 
proliferation.  
Inflammation  and oxidative stress 
The role of RSV in colitis and inflammation-associated tumorigenesis has been best 
studied using the irritant, DSS. The addition of 0.03% RSV to the diet of mice resulted in a 
dose-dependent decrease in DSS-induced colitis and a significant decrease in AOM/DSS-
induced tumorigenesis (232). Singh and colleagues showed that RSV (100 mg/ kg body 
weight) prevented DSS-induced colitis through an increase in SIRT1 and decrease in NF-B 
that was accompanied by a reduction of serum IL-6, IL-1, IFN- and decreased macrophage 
number in lamina propria (233). In similar studies of DSS-induced colitis, RSV protected the 
colonic mucosa through attenuation of iNOS expression and NF-B activity (234,235). It is 
noteworthy for the interpretation of studies combining RSV and DSS treatments that the 
impact of RSV on DSS metabolism is currently unknown. The role of RSV in oxidative 
stress was further demonstrated by RSV-induced activation of p53 in colon cancer cells in 
response to NO production (236). 
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Cancer cell proliferation 
 In human patients given 0.5 or 1 g RSV prior to undergoing surgical resection of 
malignant colon tumors, colon cell proliferation was reduced by 5% compared to patients 
that did not receive RSV (237). Interestingly, tissue accumulation of RSV was higher on the 
right side of the colon compared to the left in these patients. It has been shown that RSV 
inhibits HT29 and SW480 colon cancer cell proliferation in part through suppression of IGF-
1R protein levels in vitro (238). In support of this, daily intake of RSV has been shown to 
also markedly decrease circulating IGF-1 and IGF binding protein-3 concentrations in mice 
(201) and humans (239). High dose RSV (100-150 M) has been shown induce apoptosis 
through activation of p53 in vitro (240) and induction of endoplasmic reticulum stress (241). 
However, this high circulating concentration of RSV is not attainable in vivo from dietary 
RSV, and as such is not a likely physiological mechanism of dietary RSV. 
Summary 
The prevalence of obesity and co-morbidities continues to rise in developed countries. 
Hypertrophic adipose tissue contributes to an obese inflammatory profile through down-
regulation of adiponectin and up-regulation of leptin, IL-6, and MCP-1. The resulting 
increase in NF-κB activation and MAPK signaling promote development of colorectal cancer 
through increased proliferation, proto-oncogene expression, and oxidative stress. 
Additionally, metabolic dysregulation associated with adiposity contributes to tumorigenesis 
through stimulation of proliferation and inflammation by hyperinsulinemia and SFAs, 
respectively. While adipose-derived cytokines and hormones have been suggested to play a 
role in the pathogenesis of colon cancer, the mechanisms have not been elucidated. The best-
studied adipokine in colorectal tumorigenesis is adiponectin. However, the literature is 
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inconsistent regarding the role of adiponectin in colon tumorigenesis with both protective and 
tumorigenic roles reported. Furthermore, the interpretation of the current literature is 
complicated by the varied cancer models and diets used. The characterization of adiponectin 
function in development of obesity-associated colorectal cancer is important for the 
development of therapeutic targets aimed at disease prevention. 
The polyphenol, RSV, has reported therapeutic potential for prevention of both colon 
cancer and obesity-related metabolic perturbations. In obesity models, RSV has been shown 
to attenuate inflammation, improve insulin sensitivity, increase fatty acid oxidation, and 
alleviate oxidative stress. Moreover, RSV mediates the adipokine profile through up-
regulation of adiponectin expression and down-regulation of pro-inflammatory cytokines and 
chemokines. RSV has also been shown to successfully inhibit multistage colon 
carcinogenesis and proliferation of colon cancer cells. The preventative role of RSV in 
obesity and colon cancer makes it a promising dietary strategy for prevention of obesity-
associated colon cancer.  However, the function of RSV in colon carcinogenesis has not been 
reported in the context of obesity. Moreover, the interaction between RSV and adipokines in 
colon cancer is not known. Sirt1 and AMPK have been identified as the primary targets of 
RSV. However, the specific roles of Sirt1 and AMPK in the anti-inflammatory function of 
RSV are unknown in the context of obesity-associated colon cancer. The elucidation of the 
mechanistic action of RSV in cell types involved in obesity-associated colon cancer is 
important for potential therapeutic target detection. Predicated on this literature base, we 
hypothesized that adiponectin regulates colon tumorigenesis through inhibition of 
inflammation in colonic epithelial cells. We further hypothesized that dietary RSV attenuates 
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colon tumorigenesis in part through increased adiponectin concentrations and subsequent 
disruption of NF-κB and AP-1 transcription factor activity. 
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CHAPTER 3. EARLY LESION FORMATION IN COLORECTAL 
CARCINOGENESIS IS ASSOCIATED WITH ADIPONECTIN STATUS WHEREAS 
NEOPLASTIC LESIONS ARE ASSOCIATED WITH DIET AND SEX IN C57BL/6J 
MICE 
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Abstract 
Adiponectin is an anti-inflammatory and insulin-sensitizing hormone that is 
decreased in obesity. Although controversial, it has been suggested that decreased 
adiponectin contributes to colorectal cancer risk in obesity. To further investigate the role of 
adiponectin in obesity-linked colorectal carcinogenesis, we utilized male and female 
adiponectin knockout (KO) and wildtype (Wt) C57BL/6J mice. Tumorigenesis was induced 
in all mice with the combined treatment of azoxymethane (AOM) and dextran sodium sulfate 
(DSS). Following AOM/DSS treatment, mice were fed a low fat, control (LFC) or high fat, 
lard (HFL) diet for 7½ weeks. We report that KO mice developed fewer total lesions than Wt 
mice, males developed fewer lesions than females, and mice fed HFL diet developed fewer 
lesions than those fed the LFC diet. Early lesion multiplicity was influenced by genotype, 
while advanced lesion development was influenced by sex and diet. Moreover, lesion types 
were differentially correlated with serum adipokines and colon gene expression of 
adiponectin receptors, insulin receptor and toll like receptor 4. These data suggest that in the 
AOM/DSS model of carcinogenesis, adiponectin functions to promote early lesion 
development whereas sex and diet are important regulators of advanced lesion development 
through pathways involved in inflammation and insulin signaling. 
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Introduction 
Adiponectin, an abundant protein secreted primarily from adipose tissue, signals 
through AdipoR1 and AdipoR2, which are expressed on many cell types (1,2,3). This 
adipokine functions to increase insulin sensitivity and reduce inflammation in adipocytes and 
other cells (4,5). As adipose tissue expands in high fat diet-induced obesity, the adipokine 
profile promotes systemic inflammation and insulin resistance through depression of 
adiponectin expression and concurrent increases in expression of pro-inflammatory 
cytokines, including IL-6, lipocalin 2 (Lcn2) and TNFα (6,7). The pro-inflammatory 
environment resulting from a high saturated fat diet increases risk for colon carcinogenesis 
(8).  
Although low serum adiponectin concentration was recently identified as a potential 
factor in development of several malignancies, including colorectal cancer (9,10,11), this 
association is controversial and is not supported in all populations reported (12). In contrast 
with its anti-inflammatory role in adipocytes, a pro-inflammatory role has been reported for 
adiponectin in colonic epithelial cells in vitro. Administration of globular and full length 
adiponectin to colonic epithelial cells resulted in stimulation of pro-inflammatory cytokine 
secretion and proliferation (13). Moreover, adiponectin receptor expression was elevated in 
colons of patients with colorectal malignancies compared to patients with normal colons, and 
in vitro, adiponectin receptors were activated by adiponectin in colon adenocarcinoma cell 
lines, suggesting that adiponectin is recognized by the colon and therefore may play a role in 
colorectal cancer development (14). In addition to adiponectin, several factors related to 
adipose tissue expansion have been correlated to risk of colorectal cancer including 
hyperinsulinemia, IGF-1 resistance, leptin resistance, and dyslipidemia (15,16,17,18,19).  
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The role of adiponectin in colonic inflammation and colorectal cancer pathogenesis 
has recently been studied in vivo through use of adiponectin- and adiponectin receptor-
deficient mice. Results of these studies are conflicting and have proposed both protective and 
promoting roles for adiponectin in dextran sodium sulfate (DSS)- or azoxymethane (AOM)-
induced inflammation and colorectal carcinogenesis (20,21,22). In addition to DSS and AOM 
treatment differences, these discrepancies may be due to treatment duration, lesion endpoint 
analysis, and high fat vs. low fat diets differences between studies. To further investigate the 
association between these parameters and adiponectin in colorectal carcinogenesis, we used 
our adiponectin deficient mouse model coupled with combined treatment of AOM and DSS-
induced carcinogenesis to which the C57BL/6 strain is highly sensitive (23). This animal 
model was designed to elucidate the roles of chronic adipose inflammation characteristic of 
high saturated fat diet-induced obesity and sex under conditions of adiponectin deficiency in 
carcinogenesis and neoplastic progression. 
Materials and Methods 
Animals. Adiponectin-deficient mice were developed by Xenogen Biosciences 
Corporation (Cranbury, NJ) using homologous recombination in mouse embryonic stem cells 
and subsequent blastocyst injection of the appropriate targeted embryonic stem cells.  The 
mouse chromosome 16 sequence (n.t.# 21,898,000~21,978,000) was retrieved from the 
Ensembl database Build 32 and used as reference. BAC clone RP23-364K13 was used for 
generating homologous arms and southern probes by PCR or RED cloning/gap-repair 
method. The 5’ homologous arm (5.3 kb) and the 3’ homologous arm (4.8 kb) were 
generated by RED cloning/gap repair. They were cloned in FtNwCD vector and confirmed 
by restriction digestion and end-sequencing. The final vector was obtained by standard 
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molecular cloning method. Aside from homologous arms, the final vector also contains FRT 
flanked Neo expression cassette (for positive selection of the embryonic stem cells), and a 
DTA expression cassette (for negative selection of the embryonic stem cells). The final 
vector was confirmed by both restriction digestion and end sequencing analysis. NotI was 
used for linearizing the final vector for electroporation. The 5’ and 3’ external probes were 
generated by PCR reaction using proofreading LA Taq DNA polymerase (Takara Bio, 
Madison, WI), and were tested by genomic Southern analysis for screening of the embryonic 
stem cells. The probes were cloned in the pCR2.1 backbone and confirmed by sequencing. 
Pups were screened via PCR specific to the Neo gene insertion and four male heterozygote 
founder mice were shipped to our laboratory at Iowa State University.  Heterozygotes were 
bred to wild type females, and offspring were genotyped. Heterozygotes were then bred to 
heterozygotes to establish the colony. 
Forty adiponectin knockout (KO) and forty wild type (Wt) mice of both sexes were 
generated for this study. Genotypes were determined by PCR of genomic DNA extracted 
from tail clips using the following primers: Forward1 
CCAACTAAGACACTGATGAAGACCTCCTG, Forward 2 
CTTTACGGTATCGCCGCTC, and Reverse CTGGGCAGGATTAAGAGGAA. Mice were 
housed individually in a climate controlled facility with 12:12 hr light:dark cycle. All 
experimental protocols for animal care and use were approved by the Institutional Animal 
Care and Use Committee at Iowa State University, Ames, Iowa.  
Study Design. A complete randomized block study design was used with blocks 
structured on the basis of age, genotype, and sex. At 6 weeks of age ± one week, each block 
of mice was moved to individual housing and acclimated on AIN-93M diet (Harlan Teklad, 
 57 
Madison, WI) for one week. At 7 weeks of age, all mice were administered a single 
subcutaneous injection of 10 mg/kg body weight AOM (Sigma-Aldrich, St. Louis, MO). 
Fresh DSS (MW 36,000-50,000, MP Biomedicals, Solon, OH) was provided daily at 1% 
(w/v) in the tap water for 4 weeks following AOM injection to facilitate tumorigenesis. Mice 
were randomly assigned to high fat, lard (HFL) and low fat, control (LFC) treatment diets, 
with 10 mice/treatment combination, which began 3 days after DSS treatment ended. The 
diet compositions were based on the AIN-93M formulation (Harlan Teklad, Madison, WI) as 
previously described with the following modification (24) the high fat diet was composed of 
36% lard by weight as the fat source with protein balanced on a caloric basis (Table 1). The 
treatment diets were fed ad libitum for 7 ½ weeks at which point the study was terminated 
due to significant weight loss. Water (with DSS) and LFC and HFL dietary intake were 
measured daily throughout respective treatment periods. DSS load (mg DSS consumed per g 
body weight) was calculated for use as a covariate in statistical analysis of colon lesions and 
inflammatory and insulin resistance endpoints. 
Sample Collection. Mice were fasted for 6-8 hours, sacrificed by CO2 asphyxiation 
and terminal blood was collected by cardiac puncture for blood glucose and serum analysis. 
Colon and gonadal fat pad samples were removed and weighed. Tissue sections 
(approximately 2 cm. in length) were taken from the distal end of the colon, flushed with 
PBS, and preserved in 10% buffered formalin for histological analysis of lesions. Remaining 
distal and proximal colon sections and fat pads were flash frozen in liquid nitrogen and 
stored at -80 °C for RNA extraction.  
Lesion Histology. To estimate the number of pre-neoplastic and neoplastic colonic 
lesions among mice in different diet and treatment groups, aberrant crypt foci (ACF), mucin 
 58 
depleted foci, adenomas, intramucosal carcinomas, and invasive carcinomas were counted in 
histologic sections of colon and the number of each lesion type per mm colon determined. 
Formalin-fixed colon samples were processed routinely for histopathology, embedded to 
allow perpendicular sectioning, sectioned at 5 microns, and sections were stained with 
hematoxylin and eosin. The total length of each sample was determined using morphometric 
analysis (Image J software, NIH) of digital photomicrographs of histologic sections of colon. 
Briefly, 20X digital images of each tissue section were collected using a Nikon Eclipse 55i 
microscope and DSFi-1 digital camera system.  Images were opened in the Image J software, 
the length of the mucosa was recorded using a free-hand line and the length analyzed using 
the “Measure” function. The sum of each image for the tissue sample was converted to mm 
by comparison with a micrometer standard.  In addition, each tissue section was evaluated 
histologically by a veterinary pathologist blinded to mouse groups and treatments. Aberrant 
crypt foci (ACF), mucin depleted foci, adenomas, intramucosal carcinomas, and invasive 
carcinomas were determined for each sample using standard histologic criteria (25,26). 
Bifurcated crypts were included as ACF. Mucin depleted foci were identified as crypts absent 
of goblet cell differentiation. The data is presented as number of ACF, early lesions (ACF 
plus mucin depleted foci), adenomas, intramucosal carcinomas plus invasive carcinomas  
(IMC+IC) and total lesions per mm colon. 
Serum Analysis. Blood glucose was measured using a commercially available 
glucometer (LifeScan, Milpitas, CA). ELISA or EIA was used to measure the following 
serum parameters: total adiponectin (R&D Biosystems, Minneapolis, MN), IL-6 (R&D 
Biosystems), leptin (R&D Biosystems) and insulin (Alpco Diagnostics, Salem, NH). Serum 
adiponectin was measured in all mice for genotype verification. However, only serum 
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adiponectin concentrations from Wt mice are reported here as adiponectin concentrations 
were not detectable in serum from KO mice.  
Quantitative Real Time PCR. Frozen adipose and colon tissue was ground in liquid 
nitrogen and RNA was isolated using acid-phenol reagent (TRIzol, Invitrogen, Carlsbad, 
CA). DNA contamination was removed using DNase-Free (Ambion, Austin, TX) and RNA 
was visualized on a diagnostic agarose gel to confirm purity. cDNA was synthesized using 
iScript (Bio-Rad, Hercules, CA). Standard curves were created for all primer pairs by cloning 
amplified cDNA into pGemT vector (Promega, Madison, WI) and sequenced to confirm the 
gene target. Primers used are listed in Table 2. Concentrations of RNA in samples were 
quantified on iCycler (Bio-Rad, Hercules, CA) using IQ™ SYBR Green Super Mix kit (Bio-
Rad, Hercules, CA). Thermal cycling conditions were 95°C for 3 min followed by 40 cycles 
of 95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 seconds. Gene expression in 
each tissue was normalized to a housekeeper gene (β-Actin or GAPDH) and expressed as log 
starting quantity. 
Statistical Analysis. Data were tested for normality and analyzed using general linear 
models analysis in SAS (Version 9.2; SAS Institute, Cary, NC) with block, genotype, diet, 
and sex considered fixed effects. Total DSS load and body weight were used as covariates for 
relevant analyses. Mean separation was performed with differences considered significant at 
P < 0.05 and tendency at P < 0.10. Correlation procedure was used to identify significant 
correlations between lesion types and serum and gene expression parameters. Data are 
presented as least square means ± s.e.m.  
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Results 
Physiological response to obesity is genotype- and sex- dependent. Mice fed the HFL 
diet gained significantly more weight and had greater adipose mass than mice fed the LFC 
diet (Table 3). Interestingly, KO mice gained significantly less than Wt mice throughout the 
dietary treatment period in both LFC and HFL diet groups. However, no genotype 
differences in gonadal fat pad weight were observed when normalized to body weight (Table 
3), nor were caloric intake (P=0.3951), initial body weight (P=0.4548) or final body weight 
(P=0.2083) different between genotypes. Although there were no differences in food intake 
between genotypes, LFC mice consumed more than HFL (P<0.0001) and females consumed 
more than males (P=0.0077) on a gram per day basis (data not shown). Because animals were 
on diet only 7 ½ weeks, serum adiponectin concentrations were not depressed in high fat 
diet-fed mice. However, there were differences in circulating glucose and insulin 
concentrations between genotypes, suggesting a role for adiponectin in insulin and glucose 
regulation (Table 3). Both serum glucose and insulin were lower in KO mice than Wt mice, 
and although the glucose:insulin ratio was not statistically different in Wt compared to KO 
and in males compared to females, there was a tendency for a positive correlation (r=0.3422) 
between serum adiponectin and glucose:insulin ratio (P=0.0595) in Wt mice. It is likely that 
after 7 ½ weeks of high fat diet feeding, the mice were at an early stage of insulin resistance 
and were beginning to compensate for loss of insulin sensitivity. Serum leptin concentrations 
were higher in the HFL diet than LFC and a diet*sex interaction was observed where males 
had higher leptin concentrations than females only in mice fed the HFL diet. No significant 
differences in serum IL-6 concentrations were identified between mice due to low detection 
levels (data not shown).  
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Incidence of AOM/DSS- induced colorectal lesions. At the time of sacrifice, both 
early and advanced lesions were detected in colons. Total lesion number per mm colon was 
significantly higher in Wt than KO mice, and there was a tendency for increased numbers of 
total lesions in females compared to males and in mice fed LFC diet compared to HFL 
(Figure 3).  Interestingly, when analyzed separately, development of early and advanced 
lesion types was affected differentially by genotype, diet, and sex effects. ACF and early 
lesions were influenced by genotype and genotype*diet interaction effects (Figure 4A, 4B). 
Specifically, Wt mice had significantly more ACF and early lesions per mm colon than KO 
mice. When genotype*diet interactions were examined, KO mice fed the HFL diet had more 
early lesions than KO mice fed the LFC diet, but in Wt mice, the LFC fed mice had a higher 
early lesion incidence than HFL fed mice. Conversely, the advanced lesion type IMC+IC was 
significantly influenced by sex and diet rather than genotype (Figure 4D). Mice fed LFC diet 
had more IMC+IC than the HFL group and females had more IMC+IC than males. 
Adenomas are intermediate in severity between early lesions and IMC+IC and were 
subsequently influenced significantly by genotype, sex, and diet effects with a tendency for 
genotype*diet interaction and genotype*diet*sex interaction (Figure 4C). Thus, as lesions 
develop and undergo progression to more malignant phenotypes in our adiponectin KO 
mouse model, the regulation of carcinogenesis switched from adiponectin-dependent to diet- 
and sex-dependent. 
Colon and adipose tissue respond differentially to high saturated fat-induced obesity. 
To evaluate whether the diet effects detected in tumor progression were associated with diet-
induced obesity, we measured the expression of genes involved in inflammation, insulin 
resistance, and adiponectin signaling in colon and adipose tissue. Both Wt and KO mice 
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responded to a high saturated fat diet with an elevation in pro-inflammatory cytokine gene 
expression in adipose tissue (Figure 5A, 5B). Both IL-6 and TNFα gene expression levels 
were significantly elevated in mice fed a high fat diet. Although genotype did not have an 
effect on IL-6 and TNFα expression itself, there was a diet*genotype interaction whereby Wt 
mice fed HFL diet had elevated TNFα and IL-6 expression compared to LFC fed mice, but 
there were no diet related differences in KO mice. Lcn2 was not affected by diet, but a 
tendency for a sex effect (P =0.0567) was detected with males expressing higher Lcn2 
transcript levels than females (data not shown).  
Colon tissue did not respond to the dietary treatment with the same inflammatory 
profile as adipose tissue (Figure 6). In colon, there were no diet-induced differences in TNFα 
(P = 0.8159) or TLR4 (P = 0.5170) gene expression between treatment groups (data not 
shown). It is possible that in our model DSS-induced inflammation is negating the effect of 
diet on colonic inflammation. However, AdipoR1 gene expression was reduced in mice fed 
the HFL diet (Figure 6A). There was a tendency for an effect of a genotype*sex interaction 
in AdipoR2 expression whereby expression was highest in male KO mice and female Wt 
mice (Figure 6B). We also detected a tendency for genotype*diet in insulin receptor, 
whereby KO mice had higher insulin receptor expression in the group fed LFC diet while Wt 
mice had higher insulin receptor expression in mice fed the HFL diet (Figure 6C). Thus, 
colonic tissue responds to diet-induced obesity with regulation of adiponectin receptor and 
insulin receptor expression in the absence of an inflammatory response to diet.  
Specific lesions are correlated with different serum and tissue parameters. To 
understand the associations between inflammation, insulin resistance, and tumor progression, 
we correlated specific colonic epithelial lesion types with serum and tissue parameters 
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(Table 4). Final body weight and fat pad weight are negatively correlated with advanced and 
total colonic lesions and serum insulin concentrations are negatively correlated with adenoma 
development. Conversely, blood glucose concentration is positively correlated with early, 
advanced, and total lesion development. Interestingly, although adiponectin and leptin alone 
are not significantly correlated to lesion number, a strong positive correlation was observed 
between serum adiponectin:leptin ratio and numbers of advanced and total colonic lesions. 
AdipoR1, TLR4, and insulin receptor expression are positively correlated to development of 
both early and advanced lesion types while AdipoR2 is correlated only to ACF and total 
early lesions. These correlations demonstrate a possible role for adiponectin and insulin 
signaling and TLR4 expression in colonic carcinogenesis and progressive development of 
malignancy. 
Discussion 
We report herein that adiponectin KO mice have lower incidence of AOM/DSS-
induced colorectal lesions than Wt mice, and that this effect was significant in ACF, early 
lesions, adenomas, and total lesions. This finding is supported by previous literature with 
respect to DSS-induced colitis, but not AOM-induced carcinogenesis. Fayad et al. 
determined that, in mice administered 2% DSS for 5 days, mice absent in adiponectin were 
protected from colonic inflammation (22). The authors showed that adiponectin directly 
binds basic fibroblast growth factor and heparin binding epidermal growth factor, thereby 
potentially inhibiting the protective effect of these growth factors against colitis in the 
epithelium. Conversely, Fujisawa et al. showed that in AOM-induced colorectal 
carcinogenesis in mice fed a high fat diet for 20 weeks, colon polyps were increased in 
adiponectin deficient mice compared to wild type mice (27). The authors proposed that 
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adiponectin was functioning to suppress epithelial proliferation under high dietary fat 
conditions, thus preventing lesion development. However, it is interesting to note that colonic 
epithelial proliferation was increased in adiponectin deficient mice compared with wild type 
mice in both studies. This may indicate a beneficial role for adiponectin deficiency-induced 
colonic epithelial proliferation in DSS-treated mice and a harmful role for proliferation in 
AOM-treated mice.  In our model, the inflammation induced with DSS following AOM 
administration seemed to favor the previously reported DSS response with respect to the role 
of adiponectin. Collectively, these studies indicate that adiponectin appears to have the 
potential to both promote and prevent colorectal epithelial damage, and the specific role of 
adiponectin is likely determined by microenvironmental influences, carcinogen, diet, and 
stage of carcinogenesis.   
We found that AdipoR1 is decreased in colon of mice fed HFL diet regardless of 
genotype. It has been shown that level of adiponectin receptor expression decreases as 
adiponectin sensitivity declines in obesity (5). Thus, we expected that adiponectin receptors 
would decline in Wt mice fed HFL diet but that no change would be observed in KO mice. 
We also found that AdipoR1 is positively correlated to ACF and IMC+IC lesion multiplicity 
which is consistent with the report by Kim et al. showing up-regulation of AdipoR1 
expression in human colon cancer tissue compared with normal colon tissue (28). Because 
adiponectin is not functioning to regulate AdipoR1 expression in adiponectin KO mice, it is 
possible that the alterations in AdipoR1 expression we observed in our adiponectin-deficient 
model were due to the presence of alternative ligands for AdipoR1. Several signaling 
molecules have been identified that interact with AdipoR1, including endo protein disulphide 
isomerase (ERp46), APPL1, protein kinase CK2, and receptor for activated C-kinase 1 
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(RACK1) (29,30,31,32). Of these signaling molecules, CK2 and RACK1 are involved in 
regulation of pancreatic beta cell signaling (33,34), a signaling cascade highly affected by 
diet-induced obesity. Moreover, CK2 and RACK1 have potential roles in regulation of colon 
tumorigenesis through regulation of apoptosis and the cell cycle (35,36). Thus, it is plausible 
that the presence of these AdipoR1 ligands may be in part responsible for the up-regulation 
of AdipoR1 expression in mice fed the HFL diet.  
To our knowledge, this is the first report of sex differences in development of pre-
neoplastic and neoplastic colonic lesions in adiponectin KO mouse model administered 
AOM/DSS. In this study, female mice developed greater adenoma and IMC+IC multiplicity 
than male mice. The development of these advanced lesions is likely due to sex-specific 
differential response to HFL diet. Males had higher insulin concentrations than females and a 
tendency for lower fat pad weight when normalized to body weight. This is supported by 
reports of sex differences in insulin regulation, inflammation, and adiposity in response to 
high fat diet (37,38). This is also supported by epidemiological data which show an 
association between sex differences and dietary factors in colorectal cancer incidence in 
humans (39). In transgenic mice with increased circulating adiponectin concentrations, a sex 
difference was observed with males developing greater tumor multiplicity than females (40). 
Another explanation for differences between sexes is hormonal disparity. Although estradiol 
has been implicated as having a role in the initiation stage of colorectal tumorigenesis (41), in 
the DSS model of colitis, estrogen increased histological scores and disease severity in 
female mice (42). Our findings are inconsistent with human epidemiological data that show 
higher incidence of colorectal cancer in males than females (43), and warrant further 
mechanistic investigation into these sex differences.  
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Mice of both genotypes responded to high fat diet as expected with an increase in the 
pro-inflammatory gene expression in adipose tissue of mice fed the HFL vs. LFC diet. 
However, diet-induced inflammation was not observed in the circulation or colonic tissue. 
This is likely due to the short duration of dietary treatment, which was sufficient for 
development of obesity and leptin resistance, but not metabolic complications. Bullen et al. 
reported that 10 wks of high fat diet feeding are needed to induce a depression in circulating 
adiponectin concentrations in mice, and that insulin concentrations are lowest at 6 weeks of 
high fat feeding and become hyperinsulinemic after 6 weeks on a high fat diet (44). Although 
diet-induced inflammation was not detectable in colon tissue, both LFC mice and females 
had more advanced lesions than HFL and male groups, respectively. We assert three possible 
reasons for this association: 1) differences in diet composition and physiological properties 
such as glycemic index (45) contributed to colorectal tumorigenesis independently or through 
interaction with genotype or sex-related parameters, 2) tumor formation may be promoted by 
a low fat diet (46) as observed by Nakamura et al. in human subjects, or 3) the different types 
and amounts of dietary fat in the LFC vs. HFL diets resulted in IGF-I and IGF-II receptor 
regulation (47) that contributed to suppression of tumor development in HFL mice. The diets 
were structured such that protein was balanced calorically. Because the LFC-fed mice 
consumed more daily feed on a weight basis but less on a caloric basis, the imbalance of both 
protein and micronutrients consumed may have contributed to diet effects. 
Herein, we show that insulin receptor expression is regulated by genotype*diet 
interaction and is positively correlated with development of ACF. This increase in insulin 
receptor expression is due in part to the tendency for increased circulating insulin in the Wt 
genotype. This finding is consistent with the literature that reports increased insulin receptor 
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expression in colonic tumors compared with normal mucosa (48). Both insulin and leptin 
have been shown to independently promote colorectal tumorigenesis (15,49). However, in 
this study, leptin is increased in mice fed the HFL diet regardless of genotype and has no 
significant association with colon lesion multiplicity. Interestingly, we observed a strong 
positive correlation between serum adiponectin:leptin ratio and numbers of adenomas, 
IMC+ICs, and total lesions that was related to the overall effect of diet on adenomas, 
IMC+IC, and total lesions. Low adiponectin:leptin ratio has been recognized recently as a 
prognostic marker related to severity and adverse outcome in colorectal cancer (50) and can 
also be used as a measure of insulin resistance (51). However, we observed increased 
severity of colonic lesions in mice with a higher adiponectin:leptin ratio, indicating the 
importance of adiponectin function in the AOM/DSS model and the previously reported 
ability of adiponectin to modulate the proliferative effects of leptin in colon epithelial cells 
(52). Thus, in our model, insulin signaling and serum adiponectin:leptin ratio, but not 
adiponectin and leptin concentrations alone, are associated with colorectal tumorigenesis.  
In summary, we report for the first time that AOM/DSS-induced colorectal 
carcinogenesis is regulated differentially to adiponectin status, sex, and diet. Early lesion 
development is determined by genotype, adenomas are determined by genotype, diet, and 
sex, and advanced colonic neoplasms are determined by diet and sex. Thus, we propose that 
molecular patterns change throughout development of colorectal cancer such that adiponectin 
plays an initial role in tumorigenesis that is subsequently regulated by diet and sex as lesions 
become more advanced. This theory is supported by the publication by Otake et al. that 
recognized serum adiponectin as a significant risk factor for early cancer and adenomas in 
patients with colorectal cancer, but found no association between adiponectin and advanced 
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cancer (53). Based on the literature, it is likely that this sequence of events is specific to 
AOM/DSS-induced colorectal cancer and not the AOM-only model of carcinogenesis. Our 
correlations indicate that insulin and glucose regulation, adiponectin signaling, and TLR4 are 
involved in these events. Future studies are warranted to identify the molecular changes 
occurring at the transition from early to advanced lesions.  
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Tables 
Table 1. Diet Composition 
 
Ingredient LFC
1 
(g) HFL
1
 (g) 
Casein
2
 140 196 
Sucrose
2
 100 100 
Corn Starch
2
 456 88 
Maltodextrin
2
 155 155 
Soybean Oil
2
 50  
Lard
2
  360 
Cholesterol
2
  1.5 
Cellulose
2
 50 50 
Vitamin Mix
2
 10 10 
Mineral Mix
2
 35 35 
Choline Bitartrate
2 
 2.5 2.5 
L-Cystine
2
 1.8 1.8 
THBQ
2
 0.008 0.008 
     Total (g) 1000.0 1000.0 
% Protein (Total kcal) 14.69 14.69 
% Carbohydrate (Total 
kcal) 73.65 25.4 
% Fat (Total kcal) 11.66 59.96 
Density (kcal/g) 3.86 5.4 
1
Adapted from AIN-93M Diet  
2
Harlan Teklad, Madison, WI 
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Table 2. Quantitative Real Time PCR Primers 
 
 
 
 
 
 
 
 
 
 
Target Forward Primer Reverse Primer 
β-Actin  TGAGAGGGAAATCGTGCGTGACAT ACCGCTCGTTGCCAATAGTGATGA 
Gapdh TCAACAGCAACTCCCACTCTTCCA ACCCTGTTGCTGTAGCCGTATTCA 
AdipoR1 TCCTGACTGGCTGAAAGACAACGA AGATGTTGCCAGTCTCTGTGTGGA 
AdipoR2 TGAGCGCTTCTTTCCTGGCAAATG ATTCCTGCAGGTTTGAGACTCCGT 
Insulin 
Receptor TTCTTTCCTGCGTGCATTTCCCAC TTAATCAGGGTGGCCAGTGTGTCT 
IL-6 TCCAGTTGCCTTCTTGGGACTGAT AGCCTCCGACTTGTGAAGTGGTAT 
TNFα  CCAACGGCATGGATCTCAAAGACA AGATAGCAAATCGGCTGACGGTGT 
Lcn2 TGCCACTCCATCTTTCCTGTT GGGAGTGCTGGCCAAATAAG 
TLR4 CCGCTCTGGCATCATCTTCATTGT TCCTCCCATTCCAGGTAGGTGTTT 
7
4
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Table 3. Body Composition and Serum Parameters 
 
 
 
 
 
Genotype Sex Diet 
Weight Gain 
(g)
a
 
Fat Pad 
Weight (g)
b
 
Glucose 
(mg/dl)
c
 
Insulin (ng/ml)
d
 
Adiponectin 
(µg/ml)
e
 
Leptin 
(ng/ml)
f
 
KO F LFC 3.8 ± 1.4
a
 1.21 ± 0.10
c
 267 ± 31
a
 0.29 ± 0.40
a
 N/A 14.2 ± 7.7
a,b
 
KO F HFL 7.3 ± 1.2
b,c
 1.24 ± 0.08
c
 283 ± 28
a,b
 0.48 ±  0.35
a,b
 N/A 28.7 ± 5.5
b,c
 
Wt F LFC 5.1 ± 1.3
a,b
 1.12 ± 0.09
b,c
 325 ± 28
a,b,c
 0.88 ±  0.32
a,b,c
 7.88 ± 0.60
b
 11.1 ± 4.9
a
 
Wt F HFL 10.2 ± 1.4
c,d
 1.22 ± 0.08
c
 312 ± 31
a,b,c
 0.64 ±  0.36
a,b,c
 7.35 ± 0.61
a,b
 25.6 ± 6.2
a,b,c
 
KO M LFC 6.3 ± 1.2
a,b
 0.89 ± 0.08
a,b
 293 ± 27
a,b
 1.40 ±  0.29
b,c
 N/A 13.3 ± 6.1
a,b
 
KO M HFL 10.8 ± 1.3
c,d
 1.24 ± 0.10
c
 341 ± 28
b,c
 1.66  ± 0.33
c
 N/A 40.5 ± 5.8
c
 
Wt M LFC 8.2 ± 1.2
b,c
 0.85 ± 0.09
a
 386 ± 27
c
 1.54  ± 0.31
c
 6.10 ± 0.65
a
 14.0 ± 5.6
a,b
 
Wt M HFL 12.7 ± 1.4
d
 1.06 ± 0.11
a,b,c
 370 ± 27
c
 2.58  ± 0.32
d
 6.45 ± 0.63
a,b
 55.9 ± 5.7
d
 
7
5
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Values are least squares means  s.e. Different letters denote statistical significance (P < 0.05). 
a 
Weight gain is calculated over 7 ½ wk. of experiment diet feeding. Significant effect of diet (5.9 ± 0.6 vs. 10.3 ± 0.6 for LFC vs. 
HFL, P < 0.0001); Significant effect of genotype (7.1 ± 0.6 vs. 9.1 ± 0.6 for KO vs. Wt, P = 0.0191); Significant effect of sex 
(6.6 ± 0.8 vs. 9.5 ± 0.8 for female vs. male, P = 0.0376) 
b
Fat pad weight normalized to final body weight.
 
Significant effect of diet (1.02 ± 0.05 vs. 1.19 ± 0.05 for LFC vs. HFL, P = 
0.0148); Significant sex effect (1.20 ± 0.06 vs. 1.01 ± 0.06 for female vs. male, P = 0.0489) 
c
 Significant effect of genotype (296 ± 13 vs. 348 ± 14 for KO vs. Wt, P = 0.0074); Tendency for sex effect (297 ± 18 vs. 347 ± 17 
for female vs. male, P = 0.0878) 
d
 Significant effect of sex (0.57 ± 0.22 vs. 1.79 ± 0.18 for female vs. male, P = 0.0004); Tendency for genotype effect (0.96 ± 0.16 
vs. 1.41 ± 0.16  for KO vs. Wt, P = 0.0511) 
e
 Significant effect of sex (7.61 ± 0.43 vs. 6.27 ± 0.47 for female vs. male, P = 0.0366) 
f
 Significant diet effect (13.2 ± 2.6 vs. 37.7 ± 2.6 for LFC vs. HFL, P < 0.0001); Significant diet*sex interaction (P = 0.0112) 
 
7
6
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Table 4. Lesion-Specific Correlations 
Data represented as correlation R (p-value).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  ACF Early Adenoma IMC+IC Total Lesions 
Serum or body composition parameter 
Final Body Weight -0.18 (0.13) -0.19 (0.11) -0.37 (0.0014) -0.32 (0.0061) -0.33 (0.0052) 
Gonadal Fat 
Weight -0.16 (0.17) -0.16 (0.19) -0.37 (0.0012) -0.31 (0.0078) -0.30 (0.0096) 
Serum Insulin -0.07 (0.59) -0.13 (0.33) -0.25 (0.05) -0.14 (0.29) -0.20 (0.13) 
Adiponectin:Leptin 0.50 (0.12) 0.59 (0.054) 0.79 (0.004) 0.69 (0.019) 0.72 (0.013) 
Blood Glucose 0.35 (0.0023) 0.34 (0.0038) 0.22 (0.069) 0.38 (0.0009) 0.37 (0.0014) 
Colon gene expression parameter (SQ) 
AdipoR1 0.29 (0.050) 0.21 (0.16) 0.11 (0.49) 0.39 (0.0073) 0.32 (0.031) 
AdipoR2 0.34 (0.030) 0.37 (0.018) 0.21 (0.19) 0.14 (0.40) 0.27 ( 0.091) 
Insulin Receptor 0.42 (0.0004) 0.34 (0.0055) 0.098 (0.44) 0.39 (0.0015) 0.35 (0.0037) 
TLR4 0.50 (<0.0001) 0.42 (0.0004) 0.17 ( 0.16) 0.50 (<0.0001) 0.41 (0.0005) 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Total lesion development is influenced by genotype, diet, and sex. 
 
Total lesions induced by AOM/DSS treatment were measured by histopathology lesion count 
per mm colon. Significant genotype effect (0.32 ± 0.04 vs. 0.46 ± 0.04 for KO vs. Wt, P = 
0.0091); Tendency for diet effect (0.43 ± 0.04 vs. 0.34 ± 0.04 for LFC vs. HFL, P = 0.0808); 
Tendency for sex effect (0.46 ± 0.05 vs. 0.32 ± 0.05 for female vs. male, P = 0.0819); 
Tendency for genotype*diet interaction (P = 0.0554).  
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Figure 4. Early lesions are influenced by genotype and diet whereas advanced lesions are 
influenced by sex.  
 
Histological analysis of early and advanced lesion number per mm colon. (A) Significant 
genotype effect (0.14 ± 0.02 vs. 0.20 ± 0.02, P = 0.0253); Significant genotype*diet 
interaction (P = 0.0330). (B) Significant genotype effect (0.18 ± 0.02 vs. 0.26 ± 0.02 for KO 
vs. Wt, P = 0.0222); Significant genotype*diet interaction (P = 0.0140). (C) Significant 
genotype effect (0.09 ± 0.01 vs. 0.14 ± 0.01 for KO vs. Wt, P = 0.0054); Significant diet 
effect (0.13 ± 0.01 vs. 0.09 ± 0.01 for LFC vs. HFL, P = 0.0388); Significant sex effect (0.16 
± 0.02 vs. 0.07 ± 0.02 for female vs. male, P = 0.0076); Tendency for genotype*diet 
interaction (P = 0.0911); Tendency for genotype*diet*sex interaction (P = 0.0900). (D) 
Significant diet effect (0.13 ± 0.02 vs. 0.07 ± 0.02 for LFC vs. HFL, P = 0.0077); Significant 
sex effect (0.13 ± 0.02 vs. 0.06 ± 0.02 for female vs. male, P = 0.0477). 
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Figure 5.  HFL diet induced a pro-inflammatory expression profile in adipose tissue. 
 
Quantitative RT-PCR gene expression analysis of adipose tissue expressed as log SQ. (A) 
Significant effect of diet (1.58 ± 0.07 vs. 1.84 ± 0.06 for LFC vs. HFL, P = 0.0047); 
Significant effect of genotype*diet interaction (P = 0.0184). (B) Significant diet effect (4.20 
± 0.06 vs. 4.44 ± 0.05 for LFC vs. HFL, P = 0.0014); Significant sex effect (4.11 ± 0.08 vs. 
4.52 ± 0.05 for female vs. male, P = 0.0008); Tendency for genotype*diet interaction (P = 
0.0943). 
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Figure 6. Diet altered AdipoR1 expression in colonic tissue. 
 
Quantitative RT-PCR gene expression analysis of colon tissue expressed as log SQ. (A) 
Significant effect of diet (2.19 ± 0.12 vs. 1.85 ± 0.12 for LFC vs. HFL, P = 0.05). (B) 
Tendency for genotype*sex interaction effect (P = 0.0645). (C) Tendency for genotype*diet 
interaction effect (P = 0.0685). 
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CHAPTER 4. LOW DOSE DIETARY RESVERATROL HAS DIFFERENTIAL 
EFFECTS ON COLORECTAL TUMORIGENESIS IN ADIPONECTIN KNOCKOUT 
AND WILD TYPE MICE 
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Abstract 
Obesity is associated with a decrease in the anti-inflammatory hormone, adiponectin, and 
increases in the circulating concentrations of multiple pro-inflammatory cytokines. These 
changes contribute to colon tumorigenesis. Resveratrol increases adiponectin production in 
adipocytes and attenuates the development of colon cancer. Thus, we hypothesized that 
adiponectin is an integral component of the mechanism by which resveratrol antagonizes 
colorectal tumorigenesis. To investigate this, we induced tumorigenesis in adiponectin 
knockout (KO) and wildtype (Wt) C57BL/6 mice through combined azoxymethane and DSS 
treatment during which mice were fed a high fat, lard-based diet (HFL), or the same diet 
containing 20 mg/kg resveratrol (HFL+R). After 14 weeks on diet, Wt mice gained more 
weight, and on a percentage basis, had higher fat mass and lower lean mass than KO mice. 
Resveratrol tended to attenuate this response in male Wt mice. Resveratrol also tended to 
reduce aberrant crypt foci development and decrease circulating interleukin 6 and insulin 
concentrations in male but not female Wt mice. Taken together, resveratrol improved overall 
health of obese Wt but not KO mice as hypothesized with a differential sex response. 
Introduction 
Visceral adiposity is highly associated with the development of colorectal cancer and 
has now been identified as an independent risk factor for colorectal cancer (1,2). Obesity is 
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associated with changes in adipose tissue that promote colon cancer development including a 
decrease in the anti-inflammatory hormone, adiponectin, and increases in leptin, insulin, and 
IL6 (3,4,5). Studies using a co-culture system or conditioned media show that adipocytes can 
stimulate proliferation of colon cancer cells (5,6). Moreover, culturing colon cancer and 
intestinal epithelial cells with adiponectin decreases inflammation, activates AMP-activated 
protein kinase (AMPK), and decrease proliferation (7).  
Resveratrol (3,5,4’ trihydroxystilbene), an activator of sirtuin 1 (Sirt1) and AMPK, is 
a compound naturally found in grapes and red wine. Resveratrol has been studied extensively 
for its anti-inflammatory and anti-carcinogenic properties. Several groups have demonstrated 
that resveratrol supplementation attenuates colitis and colon tumor multiplicity in mice 
exposed to dextran sodium sulfate (DSS) and azoxymethane (8,9,10,11).  In vitro studies to 
determine the mechanism of resveratrol indicate an inhibitory effect on pro-inflammatory 
gene expression, including toll like receptor 4 (12) and cyclooxygenase 2 (13), and decreased 
proliferation of colonocytes (14). 
Recently, a role for resveratrol in modulating the adipokine profile has been 
established in the literature. The addition of resveratrol to a high fat diet increased 
mitochondrial number and improved insulin sensitivity and the overall metabolic profile in 
obese mice (15).  In vitro studies of resveratrol signaling in adipocytes show attenuation of 
inflammation via inhibition of nuclear factor kappa B (16), and inhibition of adipogenesis 
(17,18) through a down-regulation in peroxizome proliferator-activated receptor  and other 
adipogenic genes. Importantly, resveratrol increases adiponectin expression in human 
visceral adipocytes (19) and 3T3-L1 adipocytes (20).    However, the role of resveratrol in 
colorectal cancer development and the potential interaction between resveratrol and 
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adiponectin has not been reported in the context of obesity.  We used adiponectin knockout 
mice, coupled with diet-induced obesity, to test the hypothesis that adiponectin mediates the 
anti-inflammatory and anti-carcinogenic effects of resveratrol in obesity. This investigation 
was focused on early lesion development, which we have previously reported to be 
modulated by low dose dietary resveratrol (21). 
Materials and Methods 
Animals and Diets. Forty adiponectin knockout (KO) and sixty wildtype (Wt) male 
and female mice were generated using our previously established colony (22). Complete 
randomized block design was used with blocks consisting of at least one animal from each 
diet*sex*genotype combination. At 6 weeks of age ± 1 week, mice were moved to individual 
housing and acclimated on AIN-93M diet (Harlan Teklad, Madison, WI) for 1 week. 
Following acclimation, all mice were administered a single injection of 10 mg/kg body 
weight AOM (Sigma Aldrich, St. Louis, MO) immediately followed by 5 days of 1% DSS 
(MW 36,000-50,000, MP Biomedicals, Solon, OH) in drinking water. DSS water intake was 
measured daily, and was used to calculate DSS load (mg DSS consumed per g body weight) 
for use in statistical analyses. Concurrent with the start of AOM/DSS administration, forty 
Wt and forty KO mice were randomly assigned one of two diets: high fat lard (HFL) or high 
fat lard with resveratrol (HFL+R). An additional twenty Wt mice were maintained on the 
AIN-93M low fat control (LFC) diet for validation of high fat diet-induced obesity. The diet 
compositions are as previously reported (22) with the addition of 20 mg/kg diet resveratrol 
(Sigma Aldrich, St. Louis, MO) in the HFL+R diet (Table 5) to represent the amount 
attainable from a low-dose dietary resveratrol aglycone supplements. Experimental diets 
were fed ad libitum for 14 weeks throughout which body weight and dietary intake were 
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measured daily. Animals were housed in a climate controlled facility with a 12:12 hr 
light:dark cycle. All experimental protocols for animal care and use were approved by the 
Institutional Animal Care and Use Committee at Iowa State University, Ames, Iowa. 
Sample Collection. Prior to sacrifice, animals were fasted for 6-8 hrs. Animals were 
sacrificed by CO2 asphyxiation followed by terminal cardiac puncture for serum collection. 
Gonadal fat pad and colon tissues were excised and weighed. Distal colon sections 
(approximately 2 cm long) were rinsed in PBS and placed in buffered formalin for lesion 
histology. Gonadal fat pad and carcasses were flash frozen in liquid nitrogen and stored at -
80ºC.  
Lesion Histology. Colons were sectioned to allow for histologic analysis of the tissue 
and the use of remaining colonic tissue for molecular analyses. Aberrant crypt foci (ACF), 
mucin depleted foci, and adenomas were counted in representative histologic sections of 
distal colon and the number of each lesion type per mm colon determined.  Formalin-fixed 
colon samples were processed routinely for histopathology, embedded to allow perpendicular 
sectioning, sectioned at 5 µm, and stained with hematoxylin and eosin. Briefly, 20X digital 
images of each tissue section were collected using a Nikon Eclipse 55i microscope and DSFi-
1 digital camera system. The total length of each sample was determined using morphometric 
analysis (Image J software, NIH) of digital photomicrographs of histologic sections of colon. 
The sum of each image for the tissue sample was converted to mm by comparison with a 
micrometer standard. A veterinary pathologist blinded to mouse treatment groups evaluated 
each tissue section histologically. Aberrant crypt foci (ACF), mucin depleted foci, and 
adenomas were determined for each sample using standard histologic criteria (23,24). 
Bifurcated crypts were included as ACF. Mucin depleted foci were identified as crypts absent 
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of goblet cell differentiation. The data is presented as number of ACF and total lesions per 
mm colon. 
Body Composition. Frozen mouse carcasses (excluding blood, gonadal adipose tissue, 
and colon) were thawed to room temperature. Following system calibration, fat mass and 
lean body mass was determined using an EchoMRI whole body composition analyzer 
(Houston, TX). Composition analysis was also performed on 10 grams of gonadal fat pad 
samples from a representative sample of mice fed each diet for use as a correction 
coefficient. The correction coefficients for respective diets were applied to the weight of 
removed adipose tissue from each mouse, and the carcass composition data adjusted 
accordingly to obtain whole body composition. Whole body percent fat and lean were 
calculated by dividing total weight of fat (g) and lean (g) by whole body weight (g), 
respectively. 
Adipocyte Size. Frozen gonadal fat pads samples (n = 4 per diet*genotype*sex 
combination) were fixed in 10% buffered formalin overnight and processed routinely for 
histologic sections. Five µm sections were stained with hematoxylin and eosin. To analyze 
for adipocyte size and number, four fields were captured at 20X magnification for each 
mouse. Adipocyte area was determined using AxioVision v4.8.2.0 (Carl Zeiss, Germany).  
Serum Analyses. Blood glucose was measured by commercial glucometer (LifeScan, 
Milpitas, CA). Serum from terminal blood collection was assayed by ELISA or Multiplex. 
Total and high molecular weight adiponectin was measured by ELISA (Alpco Diagnostics, 
Salem, NH). Insulin, MCP1, IL6, TNF, and leptin were measured using a 5-plex Milliplex 
Mouse Adipokine kit (Millipore, Billerica, MA) on a multiplex system (Bioplex, BioRad, 
Hercules, CA). 
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Caco-2 and Stromal Vascular Cell Culture 
 Caco-2 Culture. Caco-2 cells (ATCC, Manassas, VA) (passage 18) were cultured at 
37C, 5% CO2 in Dulbelco’s Modified Eagle Medium (DMEM, Sigma Aldrich, St. Louis, 
MO) with 10% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT), 100 U/ml 
penicillin/100 µg/ml streptomycin, and 1% non-essential amino acids (MEM, Gibco, 
Billings, MT). 
 Stromal Vascular Cell Isolation. Stromal vascular cells (SVCs) were isolated from 
gonadal fat pads of Wt and KO mice obtained from the adiponectin null breeding colony. 
Briefly, adipose tissue was excised, placed in cold 1x HBSS buffer, and minced. Tissue was 
then digested in 50% HBSS/50% LG-DMEM medium with 200 U/ml collagenase shaking 
for 1 hr. at 37ºC. Digested cells were centrifuged 5 min, 1,000 x g and digestion media was 
removed. Cells were then incubated at room temperature in red blood cell lysis buffer (0.154 
M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) and centrifuged at 1,000 x g to remove red blood 
cells. Remaining cells were re-suspended in LG-DMEM growth medium and passed through 
a 100 µm filter to isolate the SVC fraction. SVCs were grown to passage 2 under 37C, 5% 
CO2 in LG-DMEM growth medium with 10% FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 0.1 mg/ml gentamicin and amphotericin B.   
Experiment 1. Wt and KO SVCs were plated according to manufacturer’s instructions 
and allowed to adhere for 2 hr. For measure of cell proliferation, media was removed and 
fresh medium containing 0, 25, or 50 M resveratrol aglycone (Sigma Aldrich, St. Louis, 
MO) and BrdU reagent (Chemicon International, Temecula, CA) was added to the cells. 
BrdU incorporation was measured after 18 hr. The same procedure was followed for Caco-2 
cells with 6 hr BrdU reagent incubation before measurement. 
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Experiment 2. Wt and KO SVCs (passage 2) were grown to 80% confluence and 
differentiated using a previously described protocol (25). At Day 11 post-differentiation, the 
cells were pre-treated for 18 hr. with fresh medium containing 0 or 25 µM resveratrol 
aglycone (Sigma Aldrich, St. Louis, MO) in DMSO. After 18 hr. pre-treatment, 100 ng/ml 
LPS was added to the medium for an additional 24 hr. treatment. The culture medium was 
collected for measurement of mouse IL6 concentration by ELISA (R&D Systems, 
Minneapolis, MN). 
The inflammatory response of Caco-2 cells to resveratrol and adiponectin was 
measured using conditioned media. The conditioned media was obtained by applying fresh 
medium (with 1% fetal bovine serum) to fully differentiated Wt and KO adipocytes for 24 hr. 
Caco-2 cells were incubated for 18 hr. in unconditioned or conditioned medium from Wt or 
KO adipocytes with DMEM containing 0 or 25 µM resveratrol. After pre-treatment, 10 
µg/ml LPS and 50 ng/ml TNFα (Sigma Aldrich, St. Louis, MO) were added to the culture 
medium, and cells were incubated for and additional 24 hr. Culture medium was collected for 
cytokine analysis of human IL6 and IL1 by ELISA (R&D Systems, Minneapolis, MN). All 
experiments had a minimum of 4 samples per treatment. 
Statistical Analyses. All residuals were plotted and tested for normality. Data were 
analyzed using general linear models procedure in SAS (Version 9.2; SAS Institute, Cary, 
NC). In the mouse experiment, genders were analyzed separately with diet, genotype, and 
block considered fixed effects with the following exception. Those data containing only Wt 
mice (serum adiponectin and LFC diet weight, intake, and blood glucose data) were analyzed 
with gender, diet, and block considered fixed effects. Body weight and DSS intake were used 
as covariates in relevant analyses. For cell culture studies, genotype of SVCs or conditioned 
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media and treatment (resveratrol or LPS) were considered fixed effects. Data is reported as 
least square means  s.e.m. Statistical significance is defined as p < 0.05 and tendency for 
significance as p < 0.1.  
Results 
Weight gain and dietary intake. We first confirmed diet-induced obesity in Wt mice 
by showing Wt mice gained significantly more weight when fed the HFL diet as compared to 
the LFC diet (Figure 7). Adiponectin genotype altered weight gain in male mice (P = 
0.0009), but not females, when fed the HFL diet (Figure 8A). Interestingly, resveratrol had a 
tendency to decrease weight gain in the Wt but not KO genotype in both male (P = 0.057) 
and female (P = 0.059) mice. These observed differences in weight gain were not due to 
differences in dietary intake (Figure 8). 
Body composition and adipocyte size. Overall, male Wt mice had significantly higher 
percent body fat and lower percent lean mass than male KO mice (Figure 9A,B). There was 
a tendency for the HFL+R diet to reduce percent body fat (P = 0.077) and increase percent 
lean mass (P = 0.087) in Wt male mice (Figure 9A,B). This HFL+R diet effect was not 
observed in KO male mice, suggesting that resveratrol has a tendency to attenuate high fat 
diet-induced adiposity only in the presence of adiponectin. In contrast, there were no 
significant diet or genotype effects on body composition observed in female mice, likely as a 
result of the greater variability observed within treatments (Figure 9C,D). 
 Analysis of adipocyte size further demonstrated a dimorphic sex response to genotype 
and experimental diets. In male mice, a genotype effect, but not a dietary effect, was 
observed in which a greater average adipocyte size was observed in Wt male mice than in 
KO male mice (Figure 10A). Conversely, females exhibited a significant diet effect, but not 
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a genotypic effect (Figure 10C). In female mice, adipocyte area was larger in HFL-fed mice 
than in HFL+R fed mice. This effect was significant for the Wt genotype with a tendency for 
significance in the KO genotype.  
ACF and total lesion development. Aberrant crypt foci (ACF) were the most abundant 
lesion type observed in the distal colon of all mice. In addition to ACF, mucin depleted foci 
and adenomas were observed, although primarily in females. Overall, there were no 
significant differences in lesion number between diet and genotype groups in males or 
females. However, there was a tendency for a genotype*diet interaction in ACF (P = 0.066) 
and total lesions (P = 0.092) of male mice (Figure 11A,B). Specifically, the HFL+R diet 
tended to decrease ACF and total lesion development (P = 0.095, P = 0.0773, respectively) in 
Wt male mice but had no effect on KO male mice (Figure 11A,B). In female mice, ACF and 
total lesions tended to be greater in Wt compared to KO genotypes (P = 0.062 and P = 0.096, 
respectively), but no interaction between diet and genotype was observed (Figure 11C,D).  
Serum Parameters. Serum insulin was significantly elevated in Wt male mice 
compared to KO male mice in males (Tables 12A, 2B).  However, HFL+R diet attenuated 
the elevation in Wt insulin concentrations with no effect on KO mice. The glucose:insulin 
ratio, an indicator of insulin sensitivity to glucose, tended to be higher in male KO mice 
compared to male Wt (P = 0.099). Females did not display diet- or genotype-dependent 
differences in glucose and insulin concentrations or glucose:insulin ratio. Thus, whereas 
glucose homeostasis had a tendency to be improved by resveratrol in Wt male mice, female 
mice were not responsive to dietary resveratrol. 
There was a tendency for higher serum total adiponectin concentrations in HFL+R 
fed mice compared to HFL fed mice for both Wt males (P = 0.094) and Wt females (P = 
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0.099) (Tables 6A, 6B). However, there were no differences observed between levels of high 
molecular weight adiponectin in mice of either sex fed either diet or in the ratio of HMW 
adiponectin:total adiponectin (data not shown). Serum IL6 concentrations in males were 
significantly affected by both diet (P = 0.043) and genotype (P = 0.021) with concentrations 
higher in HFL compared to HFL+R and in Wt mice compared to KO. Interestingly, there was 
a tendency (P=0.061) for a decrease in IL6 concentrations of mice fed HFL+R compared to 
HFL in Wt but not KO male mice. Serum MCP1 concentrations were similarly affected by 
both diet and genotype in male mice. However, in contrast to IL6 regulation, MCP1 was 
significantly decreased by HFL+R diet compared to HFL only in KO male mice. Leptin and 
TNF concentrations were not affected by diet or genotype in males or females. 
Furthermore, female mice did not demonstrate any diet or genotype effects with regard to 
IL6 or MCP1 serum concentrations.  
Lesion and serum correlations. A distinct sexual dimorphism exists in the correlation 
between serum parameters and colon lesions (Table 7). In males, ACF number was 
negatively correlated to total adiponectin (P = 0.03) and positively correlated to MCP1 (P = 
0.02) and TNFα (P = 0.098) concentrations. These correlations were reflected in total lesion 
number.  In addition, there was a tendency for a negative correlation between total lesions 
and serum leptin concentration (P = 0.07). In females, ACF and total lesions were not 
correlated with adiponectin and leptin concentrations but were both strongly positively 
correlated with serum IL6 (P < 0.0001) and TNF (P < 0.0001).  
Stromal vascular cell (SVC) and Caco-2 proliferation and inflammation. To further 
investigate the interaction between adiponectin and resveratrol in adipocytes and colon 
cancer cells, we studied SVCs isolated from gonadal adipose tissue from Wt and KO mice 
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and Caco-2 colon cancer cells (Figures 12,13). Basal SVC proliferation was significantly 
greater in KO than Wt SVCs (Figure 12A). This demonstrated a clear phenotype difference 
between adiponectin KO and Wt SVCs prior to differentiation and endogenous adiponectin 
production by Wt cells. Treatment of the cells with resveratrol lowered KO cell proliferation 
to the level of Wt cells, but had no effect on Wt cell proliferation. We then measured 
proliferation of Caco-2 colon cancer cells treated with media conditioned from differentiated 
Wt or KO SVCs.  These conditioned medias contained 0.21 ng/ml and 0.02 ng/ml 
adiponectin, respectively. The Caco-2 cells treated with KO SVC-conditioned media had 
higher basal proliferation than those treated with Wt SVC-conditioned media, but both 
treatments caused increased proliferation when compared to the unconditioned media control 
(Figure 12B). Resveratrol treatment reduced proliferation in cells treated with both KO- and 
Wt-conditioned media to the level of proliferation in unconditioned media. Thus, despite 
increased proliferation in the absence of adiponectin, the effect of resveratrol on proliferation 
of SVCs and Caco-2 cells is not dependent on adiponectin. 
We then measured the response of adipocytes and colon cancer cells culture in 
conditioned media to inflammatory stimuli initiated by LPS or LPS/TNFα, respectively. 
Differentiated KO SVCs had greater basal IL6 production than Wt SVCs.  In both cell types, 
IL6 secretion was significantly elevated with the addition of LPS (Figure 13A). 
Interestingly, resveratrol treatment lowered LPS-induced inflammation as measured by IL-6 
concentration in Wt cells but not in KO cells. Conversely, Caco-2 cells treated with KO 
SVC- or Wt SVC-conditioned media had uniformly low basal IL6 production, but were both 
responsive to LPS/TNF treatment (Figure 13B). Moreover, resveratrol treatment 
effectively reduced IL6 production to basal levels in LPS/TNF stimulated KO SVC- and Wt 
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SVC-conditioned Caco-2 cells. Therefore, resveratrol effectively attenuated LPS-induced IL6 
production in Wt but not KO adipocytes, but was effective in reducing LPS/TNF-induced 
IL6 production in KO SVC-conditioned and Wt SVC-conditioned Caco-2 cells.  
Discussion 
 Herein we show a tendency for attenuation of early lesion development by resveratrol 
that is dependent on the presence of adiponectin in male mice. Moreover, male mice had a 
significant negative correlation between serum adiponectin and ACF. To our knowledge, this 
is the first report of this interaction in the context of obesity-associated colon carcinogenesis. 
Interestingly, this interaction is not evident in female mice. This sex disparity is most likely 
explained by the influence and variability associated with female reproductive hormones. In 
support of this, two studies have demonstrated an interaction between female reproductive 
hormones and obesity-related insulin signaling and inflammation in mouse models using 
established colon cancer lines (26,27). However, the effect of reproductive hormones is not 
well characterized under tumorigenic conditions. 
We also showed that resveratrol-associated improvement in the co-morbidities of 
obesity were evident primarily in Wt male mice. Specifically, Wt male mice fed HFL+R diet 
showed a tendency for reduced weight gain, increased percent lean mass, decreased percent 
body fat, and overall improved serum profile. We propose three possible explanations for this 
finding: 1) The improvement in the serum profile of Wt male mice may be in part due to the 
tendency for resveratrol to increase serum adiponectin concentration as we hypothesized. 
However, resveratrol also tended to increase serum adiponectin in females without a parallel 
improvement in serum inflammatory and glucose metabolism endpoints. This illustrates a 
sexual dimorphic response to resveratrol and adiponectin that may be simply due to the more 
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variable response of female mice to carcinogen and dietary treatments. 2) In addition to 
actions mediated via adiponectin, it is possible that resveratrol had inhibitory effects on the 
elevated adipogenesis and inflammation of Wt mice through Sirt1. This role for resveratrol 
has been previously demonstrated in vivo and in vitro (16,17,28) 3) Wt mice were more 
obese and had a more pro-inflammatory profile than KO mice. This discrepancy may explain 
the more measureable effect of resveratrol on Wt mice. 
Although Kineman et al. has previously reported an attenuation of AOM-induced 
ACF formation with the same resveratrol dose in a low fat diet (21), the lack of a statistically 
significant response to resveratrol in the present study is likely due to profound DSS- and 
obesity-induced colonic inflammation. However, differences between ACF assessment 
methods and colon regions assessed between the studies could also contribute to the lack of 
significance observed. It is possible that with a greater dietary resveratrol dose, significant 
results may be obtainable in this obesity model.  
In SVC culture, we showed that resveratrol is more effective at attenuating LPS-
induced inflammation in Wt compared to KO adipocytes. This supports our hypothesis that 
the anti-inflammatory effect of resveratrol is enhanced by adiponectin. However, basal IL6 
production is higher in KO adipocytes than Wt adipocytes. This is in contrast to our in vivo 
results showing higher circulating IL6 in Wt than KO mice. We also showed that resveratrol 
was able to reduce proliferation in KO- and Wt-conditioned media treated Caco-2 cells to the 
same level. The discrepancy between our in vivo and in vitro experiments is most likely due 
to differences in resveratrol dose and cancer stage, thereby demonstrating the importance of 
in vivo studies to assess the role of dietary and endogenous signaling molecules on 
tumorigenesis. The resveratrol doses used in cell culture were chosen to provide a 
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mechanistic analysis of resveratrol actions on Wt and KO conditions. However, the cell 
culture doses used would likely not be obtainable in mice fed our low dose resveratrol 
treatment diets. It is also important to note that the form of resveratrol used in these studies 
(trans-resveratrol aglycone) is not the form present naturally in foods but rather is the form 
of resveratrol typically used in supplements. 
In conclusion, we report a potential effect of resveratrol on obesity-associated colon 
tumorigenesis in male mice that is not evident in the absence of adiponectin. Moreover, we 
present a dimorphic gender response to resveratrol and carcinogen treatment. Further studies 
focusing on resveratrol dosage and this sexual dimorphic response are warranted to improve 
our understanding of the interaction between resveratrol and adiponectin in colon cancer 
development. 
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Tables 
Table 5. Diet Composition 
Ingredient LFC
1
 HFL
1
 HFL+R
1
 
Casein
2
 140 196 196 
Sucrose
2
 100 100 100 
Corn Starch
2
 456 88 88 
Maltodextrin
2
 155 155 155 
Soybean Oil
2
 50   
Lard
2
  360 360 
Cholesterol
2
  1.5 1.5 
Cellulose
2
 50 50 50 
Vitamin Mix
2
 10 10 10 
Mineral Mix
2
 35 35 35 
Choline Bitartrate
2 
 2.5 2.5 2.5 
L-Cystine
2
 1.8 1.8 1.8 
THBQ
2
 0.008 0.008 0.008 
Resveratrol Aglycone
3
     0.02 
     Total (g) 1000.0 1000.0 1000.0 
% Protein (Total kcal) 14.69 14.69 14.69 
% Carbohydrate (Total kcal) 73.65 25.4 25.4 
% Fat (Total kcal) 11.66 59.96 59.96 
Density (kcal/g) 3.86 5.4 5.4 
1
Adapted from AIN-93M Diet   
2
Harlan Teklad, Madison, WI   
3
Sigma-Aldrich, St. Louis, MO   
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Table 6 (A). Male Blood and Serum Parameters 
 
  KO Wt 
  HFL HRL+R HFL HRL+R 
Glucose (mg/dl)
a
 336 ± 22 365 ± 22 349 ± 23 320 ± 22 
Insulin (pg/ml)
b
 1745.96 ± 320.94
a
 1874.31 ± 320.94
a
 2958.22 ± 338.78
b
 2284.75 ± 320.94
a,b
 
Glucose:Insulin
c
 0.26 ± 0.05 0.26 ± 0.05 0.20 ± 0.05 0.15 ± 0.05 
Total AdipoQ (μg/ml)d N/A N/A 22.72 ± 1.02 25.34 ± 1.02 
HMW AdipoQ (μg/ml)e N/A N/A 5.32 ± 0.64 6.61 ± 0.65 
Leptin (ng/ml)
f
 11.64 ± 1.46 11.32 ± 1.39 15.33 ± 1.46 12.46 ± 1.46 
IL-6 (pg/ml)
g
 8.86 ± 1.49
a
 6.78 ± 1.41
a
 13.69 ± 1.59
b
 9.32 ± 1.58
a,b
 
MCP-1 (pg/ml)
h
 118.01 ± 13.30
b
 58.83 ± 20.86
a
 146.50 ± 17.26
b
 113.72 ± 14.10
b
 
Values are least squares means  s.e. Different letters denote statistical significance (P < 0.05). 
a
No significant treatment differences. 
b
Significant genotype effect, P = 0.018. 
c
Tendency for genotype effect, P = 0.099. 
d
Tendency for diet effect, P = 0.094. 
e
No significant treatment differences. 
f
No significant treatment differences. 
g
Significant diet effect, P = 0.043; significant genotype effect, P = 0.021. 
h
Significant diet effect, P = 0. 0.019; significant genotype effect, P = 0. 0.031. 
 
 
 
 
 
 
 
 
 
 
1
0
0
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Table 6 (B). Female Blood and Serum Parameters 
 
  KO Wt 
  HFL HRL+R HFL HRL+R 
Glucose (mg/dl)
a
 279 ± 22 330 ± 21 304 ± 21 286 ± 22 
Insulin (pg/ml)
b
 658.12 ± 135.19 902.49 ± 119.17 852.71 ± 113.55 956.64 ± 127.15 
Glucose:Insulin
c
 0.52 ± 0.10 0.49 ± 0.09 0.41 ± 0.09 0.42 ± 0.10 
Total AdipoQ (μg/ml)d N/A N/A 42.54 ± 3.58 51.61 ± 3.70 
HMW AdipoQ (μg/ml)e N/A N/A 11.17 ± 1.17 12.22 ± 1.14  
Leptin (ng/ml)
f
 4.60 ± 1.32 4.91 ± 1.19 6.61 ± 1.19 5.83 ± 1.25 
IL-6 (pg/ml)
g
 7.09 ± 1.82 7.90 ± 1.56 10.44 ± 1.49 9.69 ± 1.56 
MCP-1 (pg/ml)
h
 132.16 ± 31.36 124.81 ± 23.83 157.71 ± 65.00 176.72 ± 36.65 
a
No significant treatment differences. 
b
No significant treatment differences. 
c
No significant treatment differences. 
d
Tendency for diet effect, P = 0.099. 
e
No significant treatment differences. 
f
No significant treatment differences. 
g
No significant treatment differences. 
h
No significant treatment differences. 
 
 
 
 
 
 
 
 
 
 
 
1
0
1
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Table 7. Serum parameter and lesion correlations 
  Male Female 
Serum Parameters ACF Total Lesions ACF Total Lesions 
Total Adiponectin -0.49 (0.03) -0.40 (0.09) -0.41 (0.10) -0.41 (0.10) 
Leptin -0.25 (0.13) -0.30 (0.07) 0.16 (0.36) 0.18 (0.31) 
IL-6 -0.19 (0.26) -0.15 (0.36) 0.80 (<0.0001) 0.82 (<0.0001) 
TNF-α 0.38 (0.098) 0.43 (0.06) 0.83 (<0.0001) 0.84 (<0.0001) 
MCP-1 0.59 (0.02) 0.45 (0.08) 0.43 (0.096) 0.46 (0.07) 
Values are correlation (p-value). 
 
 
 
 
 
 
 
 
 
1
0
2
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Figures 
 
 
Figure 7. HFL causes a significant increase in weight gain and blood glucose concentrations 
of Wt mice, and this is attenuated by RSV. 
Wild type weight gain and blood glucose. (A) Significant diet effect, P < 0.001; tendency for 
sex effect, P = 0.056. (B) Significant diet effects, P = 0.0064. 
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Figure 8. RSV had a tendency to attenuate weight gain in Wt but not KO mice without 
affecting food intake. 
 
Weight gain and average daily intake. Males (A,B); Females (C,D). (A) Significant genotype 
effect, P = 0.0009. (C) Tendency for diet effect, P = 0.065. (D) Tendency for genotype effect, 
P = 0.099.  
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Figure 9. RSV had a tendency to increase percent body fat and decrease percent lean mass 
in male Wt but not KO mice. 
Percent total body fat and lean. Males (A,B); Females (C,D). (A) Significant genotype effect, 
P = 0.0045. (B) Significant genotype effect, P = 0.0077. 
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Figure 10. RSV significantly decreased adipocyte area in Wt but not KO female mice. 
Gonadal adipose tissue adipocyte size. Males (A,B); Females (C,D). (A) Tendency for 
genotype effect, P = 0.095. (C) Tendency for diet effect, P = 0.084. B,D: KO, HFL, top left; 
KO, HFL+R, top right; Wt, HFL, bottom left; Wt, HFL+R, bottom right. 
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Figure 11. RSV has a tendency to decrease AOM-induced early and total lesion number in 
male Wt but not KO mice. 
Colonic aberrant crypt foci and total lesions represented as lesion number per mm distal 
colon. Average colon section length was 39 mm, and an average of 4 lesions were counted 
per section. Males (A,B); Females (C,D). (A) Tendency for diet*genotype interaction, P = 
0.092. (B) Tendency for diet*genotype interaction, P = 0.066. (C) Tendency for genotype 
effect, P = 0.062. (D) Tendency for genotype effect, P = 0.096. (E) Representative ACF. (F) 
Representative MDF. (G) Representative adenoma. 
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Figure 12. Proliferation is attenuated in SVCs and Caco-2 cells by RSV. 
SVC and Caco-2 cell proliferation. (A) SVC BrdU incorportation. Significant effect of SVC 
genotype, P = 0.0338. Tendency for effect of RSV concentration, P = 0.0886. Significant 
SVC*RSV interaction, P = 0.0116. (B) Caco-2 BrdU incorporation. Significant effect of 
SVC genotype, P = 0.0003. Significant effect of RSV concentration, P < 0.0001. Significant 
SVC*RSV interaction, P = 0.0001. 
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Figure 13. Adiponectin interacts with RSV to attenuate LPS-induced inflammation in 
adipocytes, but not Caco-2 cells. 
SVC and Caco-2 inflammation. (A) SVC culture medium IL-6. Significant effect of SVC 
genotype, P <0.0001. Significant effect of RSV concentration, P < 0.0001. Significant 
SVC*RSV interaction, P = 0.002. (B) Caco-2 culture medium IL-6. Tendency for effect of 
SVC genotype, P = 0.07. Significant effect of RSV concentration, P < 0.0001. Tendency for 
SVC*RSV interaction, P = 0.06. 
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Abstract 
 Resveratrol (RSV) has been shown to inhibit the metabolic effects of obesity as well 
as colon tumorigenesis and has recently been shown to attenuate obesity-associated colon 
tumorigenesis. Moreover, RSV is a known activator of the mediators of inflammation, sirtuin 
1 (Sirt1) and AMP-activated protein kinase (AMPK). However, the roles of Sirt1 and AMPK 
in the anti-inflammatory function of RSV are not fully elucidated. The aim of this study was 
to compare the roles of Sirt1 and AMPK in RSV’s attenuation of LPS-induced inflammation 
among human adipocytes, HT29 colon cancer cells, and U937 monocytes. This was 
investigated through the use of EX 527, a Sirt1 inhibitor, and Compound C, an AMPK 
inhibitor.  In adipocytes, RSV attenuated LPS-induced MCP-1 production in part through 
activation of Sirt1 but not AMPK. Conversely, Compound C reversed RSV’s attenuation of 
LPS-induced lipolysis suggesting a role for AMPK in the metabolic effects of RSV. In HT29 
cells, Sirt1 mediated RSV’s effect on LPS-induced reactive oxygen species production and 
proliferation. However, RSV and EX 527 had no effect on IL-8 production. U937 cells 
exhibited LPS-induced inflammation that was attenuated by RSV with antagonistic roles of 
AMPK and Sirt1. Taken together, our data suggest that RSV elicits different molecular 
responses of AMPK and Sirt1 in the response to LPS stimulation among adipocytes, colon 
cancer cells, and monocytes. Further research is needed to elucidate how these cell and tissue 
types interact under RSV supplementation to prevent obesity-associated colon cancer.   
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Introduction 
Obesity is associated with elevated risk, reoccurrence, and mortality from colorectal 
cancer (1,2). The development of obesity-associated colon cancer requires the involvement 
of adipocytes, macrophages, and colon epithelial cell types as inflammatory mediators. The 
chronic, systemic inflammation characteristic of obesity is a result of increased adipose-
resident macrophages, adipose- and diet-derived saturated fatty acids, and increased colonic 
endotoxin transport and toll-like receptor 4 (TLR4) expression (3). Stimulation of TLR4 by 
circulating lipopolysaccharide (LPS) and saturated free fatty acids increases the activity of 
the pro-survival and pro-inflammatory transcription factors, nuclear factor-κ B (NF-κB) and 
activator protein 1 (AP-1) in adipocytes and macrophages (4). Subsequently, adipose- and 
macrophage-derived cytokines and reactive oxygen species directly contribute to colon 
tumorigenesis through promotion of survival and proliferation of damaged cells (5,6,7).  
Resveratrol (RSV, trans-3,5,4’ trihydroxystilbene), a polyphenol found naturally in 
grapes and red wine, has been demonstrated to have anti-tumorigenic and anti-obesity effects 
in human models studied in vivo and in vitro (8,9,10). Moreover, we recently demonstrated a 
tendency for RSV to attenuate obesity-associated colorectal cancer in a mouse model (11). 
Inhibition of both NF-κB and AP-1 pathways have been implicated in the action of RSV. In 
human myeloid, epithelial, and lymphoid cells, RSV was shown to prevent LPS-induced 
activation of NF-κB and AP-1 (12). Furthermore, treatment of 3T3-L1 murine adipocytes 
with LPS-stimulated RAW264.7-conditioned media resulted in ERK and NF-κB activation 
that was attenuated with RSV (13). Similarly, RSV or similar pterostilbene analogues have 
been reported to down-regulate NF-κB and p38 MAPK in HT-29 human colon cancer cells 
(14,15).  
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RSV is an activator of sirtuin 1 (Sirt1) and AMP-activated protein kinase (AMPK), 
and it is thought that Sirt1 and AMPK mediate the anti-inflammatory effects of RSV. 
Although there have been reports of the roles of Sirt1 (16,17,18,19) and AMPK (16,20) in 
the regulation of NF-κB and MAPK pathways in various cell types, the independent roles of 
RSV-induced Sirt1 and AMPK in attenuation of inflammation in obesity-associated colon 
cancer has not been fully elucidated. Moreover, we have previously shown that murine 
adipocytes and Caco-2 colon cancer cells respond differentially to RSV with respect to 
presence of adiponectin, an AMPK activator (11,21). Thus, the purpose of the experiments 
described herein was to mechanistically compare the response of cell types involved in 
obesity-associated colon cancer to RSV treatment under LPS stimulation.  
Materials and Methods 
Materials. Fetal bovine serum (FBS) and penicillin/streptomycin were purchased 
from Hyclone (Logan, UT). RPMI 1640 medium was purchased from American Type 
Culture Collection (ATCC, Manassas, VA). The NF-B p65 inhibitory peptide was 
purchased from Imgenex (IMG-2003, San Diego, CA). SB 203580, Cardamonin, EX 527, 
and Compound C were purchased from Tocris Bioscience (Ellisville, MO). All reagents not 
specified were purchased from Sigma (St. Louis, MO).  
Culturing of human adipocytes. Human subcutaneous pre-adipocytes pooled from 6 
non-diabetic, non-obese female donors were purchased from Zen Bio (Research Triangle 
Park, NC). Pre-adipocytes were cultured in low glucose DMEM with 10% FBS and 100 
U/ml penicillin and 100 µg/ml streptomycin. For differentiation to adipocytes, pre-adipocytes 
were grown to confluence and incubated in differentiation medium containing 100 nM 
human insulin, 33 μM biotin, 17 μM pantothenic acid, 0.1% ITS (insulin transferrin sodium 
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selenite) supplement, 5 μM Troglitazone, 1 μM dexamethasone, and 0.5 mM IBMX for 6 
days. Differentiation medium was removed at Day 6, and fresh medium containing 100 nM 
insulin, 33 μM biotin, 17 μM panthothenic acid, and 0.25 μM dexamethasone was applied 
every 2 days until experimental treatments were applied between Days 12-14.  
Culturing of HT29 human colon cancer and U937 human macrophages. HT29 and 
U937 cells were purchased from ATCC (Manassas, VA). HT29 cells were cultured in high 
glucose DMEM medium with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
U937 monocytes were cultured in RPMI 1640 medium with 10% FBS, 100 U/ml penicillin, 
and 100 µg/ml streptomycin. HT29 and U937 cells were plated at 1 x 10
6
 cell/ml for 
experimental treatments. 
Cell culture experiments. Differentiated human adipocytes (Day 12-14), HT29 colon 
cancer cells, and U937 monocytes were plated and cultured as described above. Treatment 
medium consisted of regular growth medium for each cell type with or without the addition 
of vehicle (0.1-0.5% DMSO), 1 μg/ml LPS, and 20 μM RSV. The following inhibitors were 
added concurrently with LPS and/or RSV treatment: 20 μM cardamonin (inhibitor of IκB 
degradation), 10 μM p65 inhibitory peptide, 20 μM SP 600125 (JNK inhibitor), 20 μM SB 
203580 (p38 inhibitor), 20 μM EX 527 (Sirt1 Inhibitor), and 10 μM Compound C (AMPK 
Inhibitor). All treatments were applied for 24 hours.  
Proliferation. BrdU reagent (Chemicon International, Temecula, CA) was applied to 
treated HT29 cells according to the manufacturers instructions and incubated for 8 hours. 
BrdU incorporation was detected by measuring absorbance at 450/550 nm. 
Reactive oxygen species production. ROS production was measured in confluent 
HT29 cells and adipocytes following the 24 hour incubation in treatment medium as 
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previously described (4). Briefly, treatment medium was removed and cells were rinsed in 
warm 1x phosphate buffered saline (PBS). The cells were incubated for 45 minutes at 37°C 
in 10 μM OxyBURST Green H2DCFDA (Invitrogen, Carlsbad, CA) in warm 1x PBS buffer. 
The detection agent was removed, and cells were rinsed 3 times with warm 1x PBS. 
Florescence was measured at absorbance and emission wavelengths of 495 nm and 527 nm, 
respectively. Data was normalized to protein concentration in each well as determined by 
bicinchoninic acid assay (BCA) (Pierce, Rockford, IL).  
Quantitative Real-Time PCR. RNA was isolated using acid-phenol reagent (TRIzol, 
Invitrogen, Carlsbad, CA), and possible DNA contamination was removed using DNase-Free 
(Ambion, Austin, TX). cDNA was synthesized using iScript (Bio-Rad, Hercules, CA). 
Standard curves were created for all primer pairs by cloning amplified cDNA into pGemT 
vector (Promega, Madison, WI) and sequenced to confirm the gene target. The primer 
sequences used are listed in Table 8. mRNA transcript abundance was quantified on an 
iCycler (Bio-Rad, Hercules, CA) with IQ™ SYBR Green Super Mix kit (Bio-Rad, Hercules, 
CA). Thermal cycling conditions were 95°C for 3 min followed by 40 cycles of 95°C for 15 
seconds, 60°C for 30 seconds, and 72°C for 30 seconds. Gene expression in each tissue was 
normalized to a housekeeper gene (β-Actin) and expressed as log starting quantity.  
Glycerol release. Glycerol release into treatment medium was measured in 
differentiated adipocytes. Free Glycerol Reagent was added to samples and standards as 
described by the manufacturer (Sigma, St. Louis, MO). Absorbance was measured at 540 nm. 
Cytokine and chemokine quantification. Secreted cytokines and chemokines were 
measured by Multiplex or ELISA. For Multiplex analysis, treatment medium was analyzed 
using the Human Cytokine/Chemokine Pre-Mixed 14 Plex Milliplex kit (Millipore, Billerica, 
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MA) on a Bioplex system (BioRad, Hercules, CA). ELISAs were used to measure human 
MCP-1 and IL-8 production in the culture medium (R&D Biosystems, Minneapolis, MN).  
Transcription factor activation. Nuclear extracts were isolated using the Cayman 
Nuclear Extraction Kit (Cayman Chemical, Ann Arbor, MI). NF-κB p65 transcription factor 
activation was measured by ELISA (Cayman Chemical, Ann Arbor, MI). AP-1 c-Jun 
transcription factor activation was measured by ELISA (TransAM AP-1 c-Jun, Active Motif, 
Carlsbad, CA). Data was normalized to protein concentration in each sample as determined 
by BCA (Pierce, Rockford, IL). 
Statistical analysis. Data was tested for normality by residual analysis. Data was 
analyzed using the general linear model procedure in SAS (Version 9.2; SAS Institute, Cary, 
NC) with culture treatment as the fixed effect. Quantitative PCR data was analyzed with 
RSV, LPS, and RSV*LPS interaction as fixed effects. Total protein concentrations or 
housekeeper mRNA transcript abundance were used as covariates for normalization of 
relevant analyses. Data is reported as least square means  s.e.m. Statistical significance is 
defined as p < 0.05 and tendency for significance as p ≤ 0.1. 
Results 
 We first compared the activation of the RSV downstream target pathways, MAPK 
and NF-κB, by LPS in monocytes, adipocytes, and colon cancer cells. A panel of 14 
cytokines and chemokines were measured in each cell type.  Each cell type expressed a 
unique cytokine and chemokine profile represented in Figure 14. In U937 monocytes, each 
inhibitor significantly attenuated LPS-induced IL-8 or MCP-1 production with the most 
robust reduction from the JNK inhibitor, SP 600125, and the non-specific NF-κB inhibitor, 
Cardamonin (Figure 14A,B). Similarly, LPS-induced IL-8 and TNF-α production were 
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significantly reduced in HT29 cells in response to all inhibitors (Figure 14C,D). Adipocytes 
showed a more variable response to the inhibitors, with a significant inhibition of IL-6 in 
response to all inhibitors and an inhibition of MCP-1 production in response to Cardamonin 
only (Figure 14E,F). Taken together, this data demonstrates that both NF-κB and MAPK 
pathways are important mediators of LPS-induced inflammatory cytokine and chemokine 
production in these cell types. 
To determine the potential roles of AMPK and Sirt1 in the regulation of LPS response 
by RSV, the AMPK and Sirt1 inhibitors, Compound C and EX 527, were utilized. In U937 
cells, AMPK or Sirt1 inhibitors in concert with RSV and LPS treatment reduced IL-8 
production greater than the combined treatment of RSV and LPS alone (Figure 15A). In 
HT29 cells, LPS increased IL-8 production, but the combined treatment of LPS and RSV was 
unable to significantly reduce LPS-induced inflammation (Figure 15B). Sirt1 inhibition 
resulted in no change in IL-8 production from that of the LPS and RSV treatment. 
Interestingly, AMPK inhibition of the LPS and RSV treatment significantly reduced both IL-
8 production and proliferation (Figure 15B, 16A). RSV decreased proliferation, and Sirt1 
inhibitor reversed the effects of RSV on ROS production and proliferation of HT29 cells 
(Figures 16A, 16B). In adipocytes, the Sirt1 but not AMPK, inhibitor reversed RSV’s 
inhibition of LPS-induced MCP-1 and ROS production. (Figures 15C, 16D). However, only 
the AMPK inhibitor significantly increased glycerol when added to the combined treatment 
of LPS and RSV in adipocytes. Thus, Sirt1 appears to be important in mediating the anti-
inflammatory effect of RSV in adipocytes and colon cancer cells while AMPK may be 
important in mediating metabolic effects. The metabolic effects of AMPK may be driven by 
RSV-induced increase in the insulin-sensitizing hormone, adiponectin. To this end, we 
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showed that RSV significantly increased adiponectin mRNA transcript abundance under 
vehicle conditions, but had no effect under LPS stimulation (Figure 17). 
To connect the pro-inflammatory endpoints to the downstream molecular targets of 
RSV, we identified the roles of AMPK and Sirt1 in transcription factor activation in the 
MAPK and NF-κB pathways. NF-κB p65 and c-Jun, a major component of the AP-1 
heterodimer, were chosen based on the successful attenuation of LPS-induced cytokine and 
chemokine production in the presence of p65 and JNK pathway inhibitors demonstrated in 
Figure 14.  In U937 monocytes under LPS stimulation, RSV had a tendency (P = 0.09) to 
decrease NF-κB p65 activation that was further decreased by Sirt1 inhibitor (Figure 18A). 
The opposite was observed for c-Jun activity whereby the AMPK inhibitor further decreased 
c-Jun activity compared to RSV’s effect on LPS (Figure 19A). In adipocytes, RSV 
significantly inhibited LPS-induced p65 activation, and RSV-induced inhibition was reversed 
to the level of LPS activation in the presence of both inhibitors (Figure 18C). The activation 
of c-Jun in adipocytes was less consistent. Interestingly, RSV significantly increased c-Jun 
activity under vehicle conditions (P = 0.001) and had a tendency to increase c-Jun activity 
under LPS stimulation (P = 0.1) (Figure 19C).  Our data suggests this effect of RSV was 
independent of AMPK or Sirt1. There was no observed effect of RSV or Sirt1 and AMPK 
inhibition on HT29 transcription factor activation (Figures 18B, 19B), suggesting that 
transcriptional regulation may be precluded by 24 hr. post-LPS stimulation in this cell type. 
Because Sirt1 was most effective in the anti-inflammatory action of RSV, we 
measured the transcriptional regulation of Sirt1 by RSV and LPS (Figure 20). In U937 and 
HT29 cells, Sirt1 transcription was elevated significantly by LPS treatment (Figures 20A, 
20B).  There was also a tendency for up-regulation of Sirt1 transcript by RSV under Vehicle 
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conditions in U937 cells (P = 0.1) and under LPS conditions in HT29 cells (0.07). In 
adipocytes, there were no significant treatment effects of RSV or LPS (Figure 20C). 
However, Sirt1 transcript had a tendency for up-regulation by RSV under vehicle conditions 
(P = 0.06) but not LPS.  
Discussion 
Adipocytes. We demonstrated herein that cell types involved in obesity-associated 
colon cancer responded to RSV by different mechanisms 24 hours after LPS stimulation. 
Adipocytes responded to LPS stimulation with elevated production of IL-6 and MCP-1, 
which was significantly attenuated by RSV. As evidenced by MCP-1 production in response 
to Sirt1 and AMPK inhibitors, Sirt1 but not AMPK in part mediated the anti-inflammatory 
effect of RSV. Similarly, Sirt1 but not AMPK reversed RSV’s inhibition of LPS-induced 
ROS generation. It is likely that the anti-inflammatory effect of RSV in adipocytes is 
mediated in part by inhibition of p65 activity. To this end, our data suggests that both AMPK 
and Sirt1 mediate RSV’s attenuation of p65 activity. Interestingly, c-Jun was increased by 
RSV independent of Sirt1 and AMPK in adipocytes. This finding is supported by a report by 
Deck et al. that showed RSV increases AP-1 activity in Hek293 cells (22). In contrast to the 
anti-inflammatory function of RSV in adipocytes, AMPK appeared to be an important 
regulator of RSV’s attenuation of LPS-induced lipolysis. Furthermore, RSV increased 
expression of the AMPK activator, adiponectin, in adipocytes. It is possible that in an in vivo 
obese scenario, this function of AMPK may indirectly impact inflammation through 
decreasing free fatty acid-induced inflammation (23). 
HT29 colon cancer cells. HT29 cells responded differentially to RSV compared to 
adipocytes. While LPS induced IL-8 and TNFα production in HT29 cells, RSV did not 
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significantly attenuate IL-8 production. In support of this, RSV has previously shown to have 
no effect on IL-8 gene expression in Caco-2 murine colon cancer cells (24). Interestingly, the 
combined treatment of AMPK inhibitor and RSV decreased IL-8 production, suggesting a 
RSV-independent role for AMPK under LPS stimulation. Sirt1 inhibition suggested a role for 
Sirt1 in mediating the attenuation of proliferation and ROS generation by RSV in HT29 cells. 
However, we did not detect an effect of RSV on p65 or c-Jun activity. This may be due to 
lack of continued LPS and RSV stimulation throughout the 24 hour treatment period or 
involvement of alternate NF-κB and AP-1 heterodimer components. 
U937 monocytes. Monocytes, although responsive to LPS and RSV, demonstrated 
opposite roles for AMPK and Sirt1. RSV attenuated LPS-induced IL-8 production, and both 
AMPK and Sirt1 inhibition amplified rather than reversed the RSV response. Similarly, Sirt1 
inhibition maximized RSV’s attenuation of p65 activity, and both AMPK and Sirt1 
maximized RSV’s attenuation of c-Jun activity. Interestingly, Sirt1 expression was elevated 
by LPS in monocytes as in HT29 cells. This may be explained by the increased Sirt1 
expression and nuclear accumulation but not activity shown by Liu et al. in development of 
LPS tolerance by a monocytic cell line (25). Conversely, RSV increased Sirt1 expression in 
HT29 but not U937 cells, suggesting that Sirt1 is differentially regulated by RSV under LPS 
stimulation between these cell types.  
Taken together, these results demonstrate that adipocytes, colon cancer cells, and 
monocytes respond to LPS stimulation with different cytokine and chemokine profiles, and 
RSV acts differentially on these inflammatory pathways among cell types. However, these 
cell types are not independent from one another in vivo. In obesity-associated colon 
tumorigenesis, monocytes infiltrate both adipose and colonic tissue, and locally interact with 
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these tissues to stimulate inflammation. Moreover, we have previously shown that the 
adipokine profile influences colon cancer cell proliferation and inflammation both in vitro 
and in vivo (11). Future in vivo studies aimed at investigating tissue-specific RSV signaling 
in obesity-associated colon tumorigenesis are warranted.  
There are limitations to this use of inhibitors that should be considered in the 
interpretation of these results.  First, the use of one inhibitor per target does not allow us to 
identify any bias or lack of specificity for that inhibitor.  For most meaningful data, multiple 
inhibitors should be used.  Second, we have not demonstrated in the cell lines used, that the 
target pathways were down-regulated by the inhibitors.  Finally, the intended specificity of 
the inhibitors for specific pathway components may not have an overall effect on the 
pathway.    
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Tables 
Table 8. Quantitative Real Time PCR Primers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Forward Primer Reverse Primer 
β-Actin  CAGCCATGTACGTTGCTATCCAGG AGGTCCAGACGCAGGATGGCATG 
Adiponectin ATCCAAGGCAGGAAAGGAGAACCT TGGTAAAGCGAATGGGCATGTTGG 
Sirt1 TCCTGGACAATTCCAGCCATCTCT TTCCAGCGTGTCTATGTTCTGGGT 
1
2
3
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Comparison of the roles of MAPK and NF-κB pathways in cytokine and 
chemokine response to LPS in the presence of specific inhibitors. 
 
SB 203580 (p38 Inhibitor), SP 600125 (JNK Inhibitor), Cardamonin (IκB degredation 
Inhibitor). (A,B) U937 monocytes, A: P < 0.0001, B: P < 0.0001. (C,D) HT29 colon cancer 
cells. C: P < 0.0001, D: P < 0.0001. (E,F) Adipocytes, E: P < 0.0001, F: P = < 0.0001. n = 8 
per treatment. 
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Figure 15. Sirt1 mediates the anti-inflammatory action of RSV.  
 
Compound C (AMPK Inhibitor), EX 527 (Sirt1 Inhibitor). (A) U937 monocytes, P < 0.0001. 
(B) HT29 colon cancer cells, P = < 0.0001. (C) Adipocytes, P = 0.0.006. n = 6 per treatment. 
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Figure 16. Roles of AMPK and Sirt1 in ROS production, proliferation, and lipolysis. 
Compound C (AMPK Inhibitor), EX 527 (Sirt1 Inhibitor). (A) HT29 proliferation, P < 
0.0001. (B) HT29 ROS generation, P = 0.0004. (C) Adipocyte glycerol release, P < 0.0001. 
(D) Adipocyte ROS generation, P < 0.0001. n = 6 – 8 per treatment. 
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Figure 17. Effect of RSV and LPS on adiponectin expression in adipocytes. 
 
 RSV P = 0.082, LPS P = 0.89, RSV*LPS P = 0.06. n = 5 per treatment. 
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Figure 18. NF-κB p65 activity is differentially mediated by AMPK and Sirt1 in monocytes, 
colon cancer cells, and adipocytes. 
 
Compound C (AMPK Inhibitor), EX 527 (Sirt1 Inhibitor). (A) U937 monocytes, P = 0.016. 
(B) HT29 colon cancer cells, P = 0.33. (C) Adipocytes, P = 0.07, n = 6 per treatment. 
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Figure 19. AP-1 c-Jun activity is differentially mediated by AMPK and Sirt1 in monocytes, 
colon cancer cells, and adipocytes. 
 
Compound C (AMPK Inhibitor), EX 527 (Sirt1 Inhibitor). (A) U937 monocytes, P = 0.008. 
(B) HT29 colon cancer cells, P = 0.03. (C) Adipocytes, P = 0.0009, n = 6 per treatment. 
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Figure 20. Sirt1 mRNA transcript abundance is regulated by RSV and LPS. 
 
Compound C (AMPK Inhibitor), EX 527 (Sirt1 Inhibitor). (A) U937, RSV P = 0.21, LPS P = 
0.03, RSV*LPS P = 0.29. (B) HT29, RSV P = 0.06, LPS P = 0.02, RSV*LPS = 0.44 (C) 
Adipocyte, RSV P = 0.20, LPS P = 0.17, RSV*LPS P = 0.20. n = 5 per treatment. 
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CHAPTER 6. GENERAL CONCLUSIONS 
The incidence of obesity has recently risen dramatically in developed countries, 
resulting in increased risk of obesity-related morbidities such as colon cancer (1,2).  
Development of obesity-linked colon cancer is accompanied by a shift to an overall pro-
inflammatory adipokine environment with decreased circulating concentrations of the anti-
inflammatory adipokine, adiponectin. The role of adiponectin in colon cancer development 
has been investigated, yielding controversial results asserting that adiponectin both protects 
and promotes colon cancer in response to different dietary and carcinogenesis models (3,4). 
RSV, a dietary polyphenol, is proposed to have anti-obesity and anti-tumorigenic effects, 
which have been attributed in part to activation of SIRT1 and AMPK activation (5). 
However, the role of RSV in obesity-associated colon cancer has not been previously 
reported. 
We first sought to investigate the role of adiponectin in obesity-associated colon 
cancer through the use of an adiponectin knockout mouse model (Chapter 3). To this end, we 
treated adiponectin KO and Wt mice with a combined AOM/DSS treatment followed by 7 ½ 
weeks of high fat or low fat diet feeding. In this study, KO mice developed fewer lesions 
than Wt mice. This finding was in contrast to the proposed role of adiponectin in AOM 
models of colon cancer (4), but consistent with its reported role in the inflammatory DSS 
model (3). Moreover, we showed that lesion formation was differentially regulated by 
genotype, diet, and sex. Specifically, early lesions were regulated by diet whereas advanced 
lesions were regulated by diet and sex. The intermediate lesion type, adenoma, was regulated 
by diet, genotype, and sex. This was the first report of a disparity between lesion stage and 
the effect of adiponectin genotype, sex, and dietary treatment.  
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Interestingly, the high fat diet promoted pro-inflammatory gene expression in adipose 
tissue but not colon. This is likely due to the robust colonic inflammatory response initiated 
by the DSS treatment. Because the DSS treatment preceded the dietary treatments, all mice 
had substantial colonic immune cell infiltration independent of dietary treatment. The 
primary difference between the DSS and AOM models is initiation of inflammation. It has 
been suggested that in the AOM model, adiponectin functions to attenuate NF-κB signaling, 
resulting in decreased proto-oncogene activation and related tumorigenesis (4). Conversely, 
in the DSS model, adiponectin may be preventing NF-κB transcribed growth factors from 
repairing damaged epithelium, thus promoting colonic damage and tumorigenesis. This 
theory is supported by the findings of Fayad et al. that showed under DSS-induced pro-
inflammatory conditions, adiponectin binds growth factors preventing the repair of damaged 
epithelium (3). Thus, it is becoming evident that adiponectin may be effective at attenuating 
colonic tumorigenesis under non-inflammatory but not pro-inflammatory conditions. These 
duel roles of adiponectin require further investigation and likely explain the highly variable 
nature of data relating adiponectin to colon cancer in the human population. 
Because we showed that the adiponectin genotype primarily influenced early lesion 
development, we used our knockout mouse model at the ACF stage to evaluate the 
interaction between RSV and adiponectin in obesity-associated tumorigenesis (Chapter 4). In 
this study, RSV had a tendency to attenuate ACF formation in Wt but not KO mice. This was 
the first report of the tendency for an interaction between RSV and adiponectin in colon 
tumorigenesis. In addition to its effects on ACF, RSV also interacted with the adiponectin 
genotype to attenuate weight gain, adipocyte size, and insulin and IL-6 concentrations. With 
the exception of adipocyte size, this interaction was observed in male but not female mice. 
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This sex difference is most likely explained by the influence of reproductive hormones. In 
support of this, two studies have demonstrated an interaction between female reproductive 
hormones and obesity-related insulin signaling and inflammation in mouse models using 
established colon cancer cell lines (6,7). However, the effect of reproductive hormones is not 
well characterized under tumorigenic conditions. 
The absence of significant dietary effects is likely due to the use of low-dose RSV in 
combination with a high saturated fat diet and DSS treatment. We hypothesize that the dose 
of RSV used (20 mg/kg diet) was insufficient to overcome these inflammatory insults both at 
the tissue and circulation levels. The lack of a low fat control baseline for gene analysis may 
have limited the detection of attenuation of inflammatory gene expression by RSV in adipose 
tissue. Moreover, the Birt laboratory has previously demonstrated that this dose of RSV is 
effective at attenuating ACF formation in a low fat control AOM rodent model that lacked 
induction of inflammation (8).  
To further investigate the interaction between RSV and adiponectin at the cellular 
level, we isolated gonadal adipose-derived stromal vascular cells from adiponectin KO and 
Wt mice for treatment with RSV. We also generated conditioned media from the 
differentiated adipose-derived SVCs for treatment of Caco-2 colon cancer cells. These 
experiments showed that in adipocytes, RSV’s action was dependent on the presence of 
adiponectin to attenuate LPS-induced inflammation. Conversely, in colon cancer cells treated 
with adipocyte-conditioned media, RSV attenuated inflammation and cell proliferation in the 
presence and absence of adiponectin. This suggested differential mechanisms of RSV action 
between cell types. 
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Finally, we sought to compare the mechanistic role of RSV in LPS-induced 
inflammation across cell types involved in obesity-associated colon tumorigenesis (Chapter 
5). For this set of experiments, we utilized human colon cancer cells, monocytes, and 
adipocytes in which we compared the roles of AMPK and Sirt1 in RSV stimulated 
attenuation of LPS-induced inflammation and ROS production through use of an AMPK and 
a Sirt1 inhibitor. Our results suggest that RSV functions differentially between these cell 
types. In adipocytes, RSV attenuated LPS-induced MCP-1 production and lipolysis, and Sirt1 
and AMPK inhibitors reversed this, respectively. The action of RSV was mediated in part by 
downstream attenuation of p65 activation. In HT29 colon cancer cells, RSV failed to 
significantly inhibit IL-8 production, but did inhibit ROS generation and proliferation. The 
addition of the Sirt1 and AMPK inhibitors suggested that this was in part through Sirt1 but 
not AMPK signaling. U937 monocytes, in contrast to adipocytes and colon cancer cells, did 
not demonstrate a role for Sirt1 or AMPK in RSV’s attenuation of IL-8 production. It is 
important to note that we did not confirm Sirt1 or AMPK inhibition by the inhibitors used, 
and the data should therefore be interpreted with this in mind. Moreover, because only one 
inhibitor was tested for each Sirt1 and AMPK, the specificity and bias of each is unknown in 
these cell lines. 
These findings led us to propose a model for RSV function in prevention of obesity-
associated colon cancer. In this model, we hypothesize that RSV acts directly on adipocytes 
in adipose tissue to inhibit inflammation and metabolic dysregulation associated with obesity 
through activation of AMPK and Sirt1. In colon epithelial cells, we hypothesize that RSV 
attenuates proliferation and ROS production in part via Sirt1 activation. Moreover, we 
hypothesize that RSV-induced reduction of inflammation in adipose tissue will further 
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attenuate inflammation and proliferation in the colon. The anti-inflammatory effects of RSV 
on both adipose and colon tissues then inhibits monocyte infiltration and the propagation of 
inflammation in these tissues. Therefore, we propose that RSV attenuates obesity-associated 
colon cancer through its direct action on adipose and colon tissues. 
Overall, we have presented evidence that adiponectin, diet, and gender interact in the 
development of obesity-associated colon tumorigenesis under pro-inflammatory conditions. 
We further demonstrated that RSV is a promising therapeutic strategy for prevention of 
obesity-associated colon cancer through its interaction with adiponectin. Finally, we showed 
that RSV signals differentially between cells types involved in obesity-associated colon 
cancer to inhibit inflammation and ROS generation. Obesity-associated colon cancer is a 
multi-factorial disease, and effective preventative therapies should target both adipose and 
colon tissue. 
The continuation of this research can proceed in several directions. First, studies can 
be aimed at resolving the seemingly opposing roles of adiponectin in colon tumorigenesis. 
This would require the use of a variety of dietary and inflammatory conditions both in vivo 
and in vitro. Additionally, the observed differences between male and female responses to 
diet and carcinogen could be investigated. Because comparisons between sexes are rarely 
made in animal studies, this research could have a large impact on both the obesity and 
cancer research fields. To further study therapeutic strategies aimed at obesity-associated 
colon cancer, there is ample opportunity for testing and identification of novel compounds 
that target RSV signaling pathways and demonstrate similar or greater bioactivity than RSV 
itself. Furthermore, our mechanistic analysis of RSV action can be expanded to additional 
human cell lines and subsequently to an in vivo tumorigenesis model. Finally, the expression 
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profile of specific colonic lesion types throughout development from healthy tissue to 
carcinoma and the effect of RSV on each lesion type can be investigated. These findings 
would help identify the ideal window of time in the progression colon tumorigenesis for RSV 
treatment.  
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